List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4848033/publications.pdf Version: 2024-02-01



DETED I RADNES

#	Article	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365.	5.6	7,792
2	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 532-555.	5.6	5,801
3	Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases. New England Journal of Medicine, 1997, 336, 1066-1071.	27.0	4,447
4	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
5	Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response. Lancet, The, 2000, 356, 2144-2148.	13.7	1,700
6	Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. New England Journal of Medicine, 1997, 337, 1405-1411.	27.0	1,478
7	Increased nitric oxide in exhaled air of asthmatic patients. Lancet, The, 1994, 343, 133-135.	13.7	1,373
8	Systemic manifestations and comorbidities of COPD. European Respiratory Journal, 2009, 33, 1165-1185.	6.7	1,365
9	Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms. Clinical Science, 1998, 94, 557-572.	4.3	1,268
10	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
11	Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2000, 343, 269-280.	27.0	1,189
12	Chronic obstructive pulmonary disease: molecular and cellularmechanisms. European Respiratory Journal, 2003, 22, 672-688.	6.7	1,174
13	Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 2008, 8, 183-192.	22.7	1,147
14	Chronic obstructive pulmonary disease in non-smokers. Lancet, The, 2009, 374, 733-743.	13.7	1,080
15	Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2016, 138, 16-27.	2.9	956
16	Sex and gender: modifiers of health, disease, and medicine. Lancet, The, 2020, 396, 565-582.	13.7	955
17	Decreased Histone Deacetylase Activity in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2005, 352, 1967-1976.	27.0	892
18	Glucocorticoid resistance in inflammatory diseases. Lancet, The, 2009, 373, 1905-1917.	13.7	850

#	Article	IF	CITATIONS
19	The cytokine network in asthma and chronic obstructive pulmonary disease. Journal of Clinical Investigation, 2008, 118, 3546-3556.	8.2	779
20	Anti-inflammatory actions of steroids: molecular mechanisms. Trends in Pharmacological Sciences, 1993, 14, 436-441.	8.7	687
21	Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12. Molecular and Cellular Biology, 2000, 20, 6891-6903.	2.3	677
22	How corticosteroids control inflammation: Quintiles Prize Lecture 2005. British Journal of Pharmacology, 2006, 148, 245-254.	5.4	650
23	Isoprostanes: markers and mediators of oxidative stress. FASEB Journal, 2004, 18, 1791-1800.	0.5	642
24	Inhaled Glucocorticoids for Asthma. New England Journal of Medicine, 1995, 332, 868-875.	27.0	605
25	Mediators of Chronic Obstructive Pulmonary Disease. Pharmacological Reviews, 2004, 56, 515-548.	16.0	604
26	Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. European Respiratory Journal, 1997, 10, 1683-1693.	6.7	595
27	Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. Journal of Experimental Medicine, 2006, 203, 7-13.	8.5	581
28	Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2013, 131, 636-645.	2.9	569
29	Oxidative Stress in COPD. Chest, 2013, 144, 266-273.	0.8	556
30	COPD as a Disease of Accelerated Lung Aging. Chest, 2009, 135, 173-180.	0.8	514
31	Histone acetylation and deacetylation: importance in inflammatory lung diseases. European Respiratory Journal, 2005, 25, 552-563.	6.7	504
32	Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respiratory Medicine, 2008, 102, 593-604.	2.9	503
33	Regional Lung Deposition and Bronchodilator Response as a Function of β <sub>2</sub> -Agonist Particle Size. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1497-1504.	5.6	482
34	Nitric oxide and asthmatic inflammation. Trends in Immunology, 1995, 16, 128-130.	7.5	478
35	New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. Journal of Allergy and Clinical Immunology, 1989, 83, 1013-1026.	2.9	463
36	A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8921-8926.	7.1	461

#	Article	IF	CITATIONS
37	Reactive oxygen species and airway inflammation. Free Radical Biology and Medicine, 1990, 9, 235-243.	2.9	460
38	Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. New England Journal of Medicine, 2018, 378, 1865-1876.	27.0	453
39	A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 549-558.	5.6	444
40	Chronic obstructive pulmonary disease. Nature Reviews Disease Primers, 2015, 1, 15076.	30.5	444
41	Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages. Journal of Experimental Medicine, 2004, 200, 689-695.	8.5	442
42	A New Approach to the Treatment of Asthma. New England Journal of Medicine, 1989, 321, 1517-1527.	27.0	435
43	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. European Respiratory Journal, 2017, 49, 1600965.	6.7	432
44	Neuropeptides in the Respiratory Tract: Part I. The American Review of Respiratory Disease, 1991, 144, 1187-1198.	2.9	424
45	Nocturnal Asthma and Changes in Circulating Epinephrine, Histamine, and Cortisol. New England Journal of Medicine, 1980, 303, 263-267.	27.0	423
46	Scientific rationale for inhaled combination therapy with long-acting β <sub>2</sub> -agonists and corticosteroids. European Respiratory Journal, 2002, 19, 182-191.	6.7	421
47	Efficacy and Safety of Inhaled Corticosteroids in Asthma. The American Review of Respiratory Disease, 1993, 148, S1-S26.	2.9	416
48	Glucocorticosteroids: current and future directions. British Journal of Pharmacology, 2011, 163, 29-43.	5.4	405
49	Theophylline. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 813-818.	5.6	402
50	Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB Journal, 1998, 12, 929-937.	0.5	398
51	Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 602-609.	2.9	386
52	Increased expression of nuclear factor-ÂB in bronchial biopsies from smokers and patients with COPD. European Respiratory Journal, 2002, 20, 556-563.	6.7	383
53	Evidence for Involvement of NF-ήB in the Transcriptional Control of COX-2 Gene Expression by IL-1β. Biochemical and Biophysical Research Communications, 1997, 237, 28-32.	2.1	382
54	Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet, The, 2000, 356, 2149-2153.	13.7	380

#	Article	IF	CITATIONS
55	p38 Mitogen-activated protein kinase–induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 649-657.	2.9	378
56	The costs of asthma. European Respiratory Journal, 1996, 9, 636-642.	6.7	376
57	As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. New England Journal of Medicine, 2018, 378, 1877-1887.	27.0	368
58	Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet, The, 2004, 363, 731-733.	13.7	364
59	Tolerance to the Nonbronchodilator Effects of Inhaled β <sub>2</sub> -Agonists in Asthma. New England Journal of Medicine, 1992, 327, 1204-1208.	27.0	356
60	A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma. New England Journal of Medicine, 1997, 337, 1412-1419.	27.0	355
61	Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. European Journal of Pharmacology, 1992, 210, 221-222.	3.5	352
62	Cellular and Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2014, 35, 71-86.	2.1	352
63	Corticosteroid effects on cell signalling. European Respiratory Journal, 2006, 27, 413-426.	6.7	348
64	Exhaled Nitric Oxide in Pulmonary Diseases. Chest, 2010, 138, 682-692.	0.8	347
65	Theophylline. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 901-906.	5.6	345
66	Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochemical and Biophysical Research Communications, 2004, 315, 240-245.	2.1	341
67	Cellular and molecular mechanisms of asthma and COPD. Clinical Science, 2017, 131, 1541-1558.	4.3	339
68	New anti-inflammatory targets for chronic obstructive pulmonary disease. Nature Reviews Drug Discovery, 2013, 12, 543-559.	46.4	332
69	Oxidative stress–induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 136, 769-780.	2.9	332
70	Nuclear factor-κB. International Journal of Biochemistry and Cell Biology, 1997, 29, 867-870.	2.8	328
71	The Cytokine Network in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 631-638.	2.9	321
72	Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 897-904.	5.6	321

#	Article	IF	CITATIONS
73	Measurement of exhaled nitric oxide in children, 2001: E. Baraldi and J.C. de Jongste on behalf of the Task Force. European Respiratory Journal, 2002, 20, 223-237.	6.7	303
74	How Do Corticosteroids Work in Asthma?. Annals of Internal Medicine, 2003, 139, 359.	3.9	300
75	Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L774-L783.	2.9	297
76	Expression and Activity of Histone Deacetylases in Human Asthmatic Airways. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 392-396.	5.6	296
77	Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 556-564.	5.6	282
78	Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 24-31.	5.6	281
79	Role of HDAC2 in the Pathophysiology of COPD. Annual Review of Physiology, 2009, 71, 451-464.	13.1	281
80	Pathophysiology of allergic inflammation. Immunological Reviews, 2011, 242, 31-50.	6.0	281
81	Induction of cycloâ€oxygenaseâ€2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. British Journal of Pharmacology, 1994, 113, 1008-1014.	5.4	278
82	Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. European Respiratory Journal, 2003, 21, 433-438.	6.7	277
83	Alveolar Macrophages as Orchestrators of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 59-70.	1.6	273
84	Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 2018, 18, 454-466.	22.7	272
85	Bradykinin–evoked sensitization of airway sensory nerves: A mechanism for ACE–inhibitor cough. Nature Medicine, 1996, 2, 814-817.	30.7	270
86	The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 753-762.	5.6	270
87	Transcription factors and asthma. European Respiratory Journal, 1998, 12, 221-234.	6.7	267
88	Mechanisms and resistance in glucocorticoid control of inflammation. Journal of Steroid Biochemistry and Molecular Biology, 2010, 120, 76-85.	2.5	264
89	Lipopolysaccharide Treatment in Vivo Induces Widespread Tissue Expression of Inducible Nitric Oxide Synthase mRNA. Biochemical and Biophysical Research Communications, 1993, 196, 1208-1213.	2.1	260
90	The effect of airway epithelium on smooth muscle contractility in bovine trachea. British Journal of Pharmacology, 1985, 86, 685-691.	5.4	258

#	Article	IF	CITATIONS
91	Oxidative Stress Induces NFκB DNA Binding and Inducible NOS mRNA in Human Epithelial Cells. Biochemical and Biophysical Research Communications, 1994, 199, 1518-1524.	2.1	257
92	Mechanisms in COPD. Chest, 2000, 117, 10S-14S.	0.8	257
93	Importance of inhaler devices in the management of airway disease. Respiratory Medicine, 2008, 102, 10-19.	2.9	256
94	Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 6-14.	5.6	255
95	Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers, 2002, 7, 1-32.	1.9	254
96	EFFECT OF A GINKGOLIDE MIXTURE (BN 52063) IN ANTAGONISING SKIN AND PLATELET RESPONSES TO PLATELET ACTIVATING FACTOR IN MAN. Lancet, The, 1987, 329, 248-251.	13.7	251
97	Neurogenic inflammation in the airways. Respiration Physiology, 2001, 125, 145-154.	2.7	250
98	Accelerated ageing of the lung in COPD: new concepts. Thorax, 2015, 70, 482-489.	5.6	250
99	Relative Corticosteroid Insensitivity of Peripheral Blood Mononuclear Cells in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 134-141.	5.6	247
100	Nitric Oxide and Airway Disease. Annals of Medicine, 1995, 27, 389-393.	3.8	246
101	New Concepts in Chronic Obstructive Pulmonary Disease. Annual Review of Medicine, 2003, 54, 113-129.	12.2	245
102	Increased 8-Isoprostane and Interleukin-6 in Breath Condensate of Obstructive Sleep Apnea Patients. Chest, 2002, 122, 1162-1167.	0.8	243
103	Rhinovirus Infection Induces Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1117-1124.	5.6	238
104	Histone Acetylase and Deacetylase Activity in Alveolar Macrophages and Blood Mononocytes in Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 141-147.	5.6	237
105	Theophylline in the management of asthma: time for reappraisal?. European Respiratory Journal, 1994, 7, 579-591.	6.7	235
106	Autoradiographic Visualization of Muscarinic Receptor Subtypes in Human and Guinea Pig Lung. The American Review of Respiratory Disease, 1990, 141, 1559-1568.	2.9	230
107	Corticosteroids: The drugs to beat. European Journal of Pharmacology, 2006, 533, 2-14.	3.5	226
108	Difficult asthma. European Respiratory Journal, 1998, 12, 1209-1218.	6.7	225

#	Article	IF	CITATIONS
109	Inhibition of PI3KδRestores Glucocorticoid Function in Smoking-induced Airway Inflammation in Mice. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 542-548.	5.6	222
110	Neutrophil Chemotactic Activity of Sputum From Patients With COPD. Chest, 2003, 123, 1240-1247.	0.8	217
111	Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. European Respiratory Journal, 1996, 9, 196-201.	6.7	214
112	Molecular Mechanisms of Corticosteroid Resistance. Chest, 2008, 134, 394-401.	0.8	214
113	Chronic Idiopathic Cough. Chest, 2005, 127, 1710-1713.	0.8	213
114	Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights. Respiration, 2011, 81, 265-284.	2.6	213
115	Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination Therapy. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 704-712.	5.6	212
116	Muscarinic receptor subtypes in airways. Life Sciences, 1993, 52, 521-527.	4.3	211
117	Exhaled leukotrienes and prostaglandins in asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 615-620.	2.9	210
118	Oxidative stress-based therapeutics in COPD. Redox Biology, 2020, 33, 101544.	9.0	210
119	Exhaled Biomarkers. Chest, 2006, 130, 1541-1546.	0.8	209
120	Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L867-L873.	2.9	208
121	Parameters associated with persistent airflow obstruction in chronic severe asthma. European Respiratory Journal, 2004, 24, 122-128.	6.7	208
122	Neuropeptides in the Respiratory Tract: Part II. The American Review of Respiratory Disease, 1991, 144, 1391-1399.	2.9	206
123	A protein deacetylase SIRT1 is a negative regulator of metalloproteinaseâ€9. FASEB Journal, 2009, 23, 2810-2819.	0.5	205
124	Therapeutic strategies for allergic diseases. Nature, 1999, 402, 31-38.	27.8	204
125	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, The, 2021, 398, 843-855.	13.7	204
126	NF-kB: a pivotal role in asthma and a new target for therapy. Trends in Pharmacological Sciences, 1997, 18, 46-50.	8.7	198

#	Article	IF	CITATIONS
127	Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4 <sup>+</sup> and CD8 <sup>+</sup> Tâ€lymphocytes: role in regulating proliferation and the biosynthesis of interleukinâ€2. British Journal of Pharmacology, 1996, 118, 1945-1958.	5.4	196
128	New therapies for asthma: is there any progress?. Trends in Pharmacological Sciences, 2010, 31, 335-343.	8.7	195
129	Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. Journal of Allergy and Clinical Immunology, 2004, 113, 1100-1108.	2.9	194
130	Pathophysiology of asthma. British Journal of Clinical Pharmacology, 1996, 42, 3-10.	2.4	193
131	A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB Journal, 2003, 17, 1298-1300.	0.5	193
132	Diagnostic Performance of an Electronic Nose, Fractional Exhaled Nitric Oxide, and Lung Function Testing in Asthma. Chest, 2010, 137, 790-796.	0.8	191
133	Increased Leukotrienes in Exhaled Breath Condensate in Childhood Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1345-1349.	5.6	190
134	Senescence in COPD and Its Comorbidities. Annual Review of Physiology, 2017, 79, 517-539.	13.1	190
135	Is Exposure to Biomass Smoke the Biggest Risk Factor for COPD Globally?. Chest, 2010, 138, 3-6.	0.8	188
136	Modulation of neurogenic inflammation: novel approaches to inflammatory disease. Trends in Pharmacological Sciences, 1990, 11, 185-189.	8.7	187
137	Treatment of airway mucus hypersecretion. Annals of Medicine, 2006, 38, 116-125.	3.8	187
138	Increased pulmonary α-adrenergic and reduced β-adrenergic receptors in experimental asthma. Nature, 1980, 285, 569-571.	27.8	186
139	Clinical aspects of exhaled nitric oxide. European Respiratory Journal, 2000, 16, 781-792.	6.7	186
140	Increased Exhaled Cysteinyl-Leukotrienes and 8-Isoprostane in Aspirin-induced Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 301-306.	5.6	186
141	The Pharmacological Properties of Tiotropium. Chest, 2000, 117, 63S-66S.	0.8	185
142	Endothelium-derived Relaxing Factor Inhibits Hypoxic Pulmonary Vasoconstriction in Rats. The American Review of Respiratory Disease, 1991, 143, 32-37.	2.9	183
143	Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochemical and Biophysical Research Communications, 2011, 406, 292-298.	2.1	181
144	lκBα Degradation and Nuclear Factor-κB DNA Binding Are Insufficient for Interleukin-1β and Tumor Necrosis Factor-α-induced κB-dependent Transcription. Journal of Biological Chemistry, 1998, 273, 6607-6610.	3.4	179

#	Article	IF	CITATIONS
145	New drugs for asthma. Nature Reviews Drug Discovery, 2004, 3, 831-844.	46.4	179
146	Prospects for new drugs for chronic obstructive pulmonary disease. Lancet, The, 2004, 364, 985-996.	13.7	176
147	Th2 cytokines and asthma: an introduction. Respiratory Research, 2001, 2, 64.	3.6	174
148	TGFÎ <sup>2</sup> 1 allele association with asthma severity. Human Genetics, 2001, 109, 623-627.	3.8	174
149	Inhaled Corticosteroids. Pharmaceuticals, 2010, 3, 514-540.	3.8	173
150	Analysis of exhaled breath condensate for monitoring airway inflammation. Trends in Pharmacological Sciences, 2002, 23, 232-237.	8.7	171
151	Repression of Cyclooxygenase-2 and Prostaglandin E2Release by Dexamethasone Occurs by Transcriptional and Post-transcriptional Mechanisms Involving Loss of Polyadenylated mRNA. Journal of Biological Chemistry, 1998, 273, 32312-32321.	3.4	168
152	Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD. Chest, 2010, 137, 1338-1344.	0.8	166
153	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	5.6	166
154	New molecular targets for the treatment of neutrophilic diseases. Journal of Allergy and Clinical Immunology, 2007, 119, 1055-1062.	2.9	164
155	Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease?. Respirology, 2015, 20, 722-729.	2.3	164
156	Cytokines as Mediators of Chronic Asthma. American Journal of Respiratory and Critical Care Medicine, 1994, 150, S42-S49.	5.6	163
157	Delayed eosinophil apoptosis in asthma. Journal of Allergy and Clinical Immunology, 2000, 106, 77-83.	2.9	163
158	Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1371-1376.	5.6	163
159	Analysis of Expired Air for Oxidation Products. American Journal of Respiratory and Critical Care Medicine, 2002, 166, S31-S37.	5.6	160
160	Distribution of Receptor Targets in the Lung. Proceedings of the American Thoracic Society, 2004, 1, 345-351.	3.5	160
161	Discovery of BRL 50481 [3-( <i>N,N</i> -dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8 <sup>+</sup> T-Lymphocytes. Molecular Pharmacology, 2004, 66, 1679-1689.	2.3	160
162	NF-κB and Activator Protein 1 Response Elements and the Role of Histone Modifications in IL-1β-Induced TGF-β1 Gene Transcription. Journal of Immunology, 2006, 176, 603-615.	0.8	160

#	Article	IF	CITATIONS
163	Oxidative Stress–induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 796-802.	5.6	159
164	Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet, The, 2001, 357, 2007-2011.	13.7	157
165	Defective Phagocytosis in Airways Disease. Chest, 2012, 141, 1055-1062.	0.8	157
166	Differential lκB Kinase Activation and lκBα Degradation by Interleukin-1β and Tumor Necrosis Factor-α in Human U937 Monocytic Cells. Journal of Biological Chemistry, 1999, 274, 19965-19972.	3.4	154
167	Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NFâ€̂PBâ€independent mechanism. FASEB Journal, 2005, 19, 1-22.	0.5	153
168	l-Arginine Increases Exhaled Nitric Oxide in Normal Human Subjects. Clinical Science, 1995, 88, 135-139.	4.3	152
169	Severe asthma: Advances in current management and future therapy. Journal of Allergy and Clinical Immunology, 2012, 129, 48-59.	2.9	151
170	Mechanisms of development of multimorbidity in the elderly. European Respiratory Journal, 2015, 45, 790-806.	6.7	150
171	Exhaled Carbon Monoxide and Nitric Oxide in COPD. Chest, 2001, 120, 496-501.	0.8	149
172	SINGLE-DOSE SLOW-RELEASE AMINOPHYLLINE AT NIGHT PREVENTS NOCTURNAL ASTHMA. Lancet, The, 1982, 319, 299-301.	13.7	148
173	Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax, 2011, 66, 521-527.	5.6	148
174	Therapeutic approaches to asthma–chronic obstructive pulmonary disease overlap syndromes. Journal of Allergy and Clinical Immunology, 2015, 136, 531-545.	2.9	147
175	Inflammatory endotypes in COPD. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1249-1256.	5.7	147
176	Glucocorticoid Resistance in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 152, S125-S140.	5.6	146
177	Regulation of Th2 Cytokine Genes by p38 MAPK-Mediated Phosphorylation of GATA-3. Journal of Immunology, 2007, 178, 2491-2498.	0.8	146
178	Measurement of Bronchial and Alveolar Nitric Oxide Production in Normal Children and Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 260-267.	5.6	145
179	Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. Journal of Leukocyte Biology, 2004, 76, 441-450.	3.3	144
180	High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respiratory Medicine, 2003, 97, 1299-1302.	2.9	143

#	Article	IF	CITATIONS
181	Reduced Histone Deacetylase in COPD. Chest, 2006, 129, 151-155.	0.8	142
182	Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. European Respiratory Journal, 2003, 21, 43-47.	6.7	140
183	CXCR3 and CCR5 Chemokines in Induced Sputum From Patients With COPD. Chest, 2008, 133, 26-33.	0.8	140
184	Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochemical and Biophysical Research Communications, 2009, 384, 366-371.	2.1	140
185	Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sciences, 1996, 60, 67-78.	4.3	139
186	Chronic Obstructive Pulmonary Disease: Effects beyond the Lungs. PLoS Medicine, 2010, 7, e1000220.	8.4	139
187	Glucocorticoids: Effects on Gene Transcription. Proceedings of the American Thoracic Society, 2004, 1, 247-254.	3.5	138
188	Dysfunction of Endothelial Progenitor Cells from Smokers and Chronic Obstructive Pulmonary Disease Patients Due to Increased DNA Damage and Senescence. Stem Cells, 2013, 31, 2813-2826.	3.2	138
189	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	6.7	138
190	Role of Potassium Channels in Bronchodilator Responses in Human Airways. The American Review of Respiratory Disease, 1992, 146, 132-136.	2.9	137
191	Increased Exhaled 8-Isoprostane in Childhood Asthma. Chest, 2003, 124, 25-31.	0.8	134
192	Localization of β-adrenoreceptors in mammalian lung by light microscopic autoradiography. Nature, 1982, 299, 444-447.	27.8	131
193	SEVERE PREMENSTRUAL EXACERBATIONS OF ASTHMA: EFFECT OF INTRAMUSCULAR PROGESTERONE. Lancet, The, 1988, 332, 370-372.	13.7	131
194	Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosanâ€stimulated respiratory burst by â€~type IV'â€selective PDE inhibitors. British Journal of Pharmacology, 1991, 103, 1339-1346.	5.4	131
195	Quantifying Proliferation of Cultured Human and Rabbit Airway Smooth Muscle Cells in Response to Serum and Platelet-derived Growth Factor. American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 574-581.	2.9	131
196	Effect of Dexamethasone and Cyclosporin A on Allergen-induced Airway Hyperresponsiveness and Inflammatory Cell Responses in Sensitized Brown-Norway Rats. The American Review of Respiratory Disease, 1992, 145, 1289-1294.	2.9	131
197	New treatments for copd. Nature Reviews Drug Discovery, 2002, 1, 437-446.	46.4	131
198	Targeting the Epigenome in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2009, 6, 693-696.	3.5	130

#	Article	IF	CITATIONS
199	Increased Leukotriene B4and Interleukin-6 in Exhaled Breath Condensate in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1109-1112.	5.6	129
200	Chronic Obstructive Pulmonary Disease: A Growing but Neglected Global Epidemic. PLoS Medicine, 2007, 4, e112.	8.4	129
201	Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis. Journal of Clinical Immunology, 2015, 35, 1-10.	3.8	129
202	Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease. , 2018, 183, 34-49.		128
203	Mechanisms of Action of Clucocorticoids in Asthma. American Journal of Respiratory and Critical Care Medicine, 1996, 154, S21-S27.	5.6	127
204	Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2005, 116, 1028-1035.	2.9	127
205	Molecular Mechanisms and Cellular Effects of Glucocorticosteroids. Immunology and Allergy Clinics of North America, 2005, 25, 451-468.	1.9	126
206	Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. Journal of Allergy and Clinical Immunology, 2010, 126, 754-762.e1.	2.9	126
207	Localization of Muscarinic Receptor Subtype mRNAs in Human Lung. American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 344-348.	2.9	125
208	Inhaled Corticosteroids in COPD: A Controversy. Respiration, 2010, 80, 89-95.	2.6	125
209	Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. European Respiratory Journal, 2003, 21, 589-593.	6.7	124
210	Autoradiographic mapping of substance p receptors in lung. European Journal of Pharmacology, 1986, 127, 295-296.	3.5	123
211	Inhaled Furosemide Inhibits Cough Induced by Low Chloride Content Solutions but Not by Capsaicin. The American Review of Respiratory Disease, 1990, 142, 143-146.	2.9	123
212	Effect of β agonists on inflammatory cellsã~†â~†â~†. Journal of Allergy and Clinical Immunology, 1999, 104, S10-S17.	2.9	123
213	p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids. Journal of Biological Chemistry, 2001, 276, 30208-30215.	3.4	123
214	The Role of Oxidative Stress in Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 255-277.	1.6	122
215	Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respiratory Medicine, 2005, 99, 703-710.	2.9	122
216	Increased p21CIP1/WAF1and B Cell Lymphoma Leukemia-xLExpression and Reduced Apoptosis in Alveolar Macrophages from Smokers. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 724-731.	5.6	121

#	Article	IF	CITATIONS
217	Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. Journal of Allergy and Clinical Immunology, 2004, 114, 761-767.	2.9	121
218	Theophylline in Chronic Obstructive Pulmonary Disease: New Horizons. Proceedings of the American Thoracic Society, 2005, 2, 334-339.	3.5	121
219	Steroid-Resistant Neutrophilic Inflammation in a Mouse Model of an Acute Exacerbation of Asthma. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 543-550.	2.9	121
220	Effects and interactions of sensory neuropeptides on airway microvascular leakage in guineaâ€pigs. British Journal of Pharmacology, 1988, 95, 1109-1116.	5.4	120
221	STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. European Respiratory Journal, 2004, 24, 78-85.	6.7	120
222	Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends in Pharmacological Sciences, 2006, 27, 546-553.	8.7	120
223	Histone Deacetylation: An Important Mechanism in Inflammatory Lung Diseases. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 445-455.	1.6	119
224	Effect of Inhaled Furosemide on Metabisulfite- and Methacholine-induced Bronchoconstriction and Nasal Potential Difference in Asthmatic Subjects. The American Review of Respiratory Disease, 1990, 142, 576-580.	2.9	118
225	Histone deacetylase-2 and airway disease. Therapeutic Advances in Respiratory Disease, 2009, 3, 235-243.	2.6	117
226	Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex. British Journal of Pharmacology, 1986, 88, 741-745.	5.4	116
227	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. Journal of Clinical Investigation, 2011, 121, 4289-4302.	8.2	116
228	Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax, 2010, 65, 263-267.	5.6	115
229	Effects of tachykinins on mucus secretion in human bronchi in vitro. European Journal of Pharmacology, 1989, 174, 283-286.	3.5	114
230	Corticosteroid Resistance in Airway Disease. Proceedings of the American Thoracic Society, 2004, 1, 264-268.	3.5	113
231	Burden and Pathogenesis of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2009, 6, 524-526.	3.5	113
232	The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways. European Journal of Pharmacology, 1992, 221, 385-388.	3.5	112
233	Effects of capsazepine against capsaicin- and proton-evoked excitation of single airway C-fibres and vagus nerve from the guinea-pig. Neuroscience, 1995, 67, 741-752.	2.3	112
234	The effect of oxidative stress on histone acetylation and IL-8 release. Biochemical and Biophysical Research Communications, 2003, 301, 572-577.	2.1	112

#	Article	IF	CITATIONS
235	The Effect of Inhaled Vasoactive Intestinal Peptide on Bronchial Reactivity to Histamine in Humans. The American Review of Respiratory Disease, 1984, 130, 162-166.	2.9	111
236	Glucocorticosteroids. Handbook of Experimental Pharmacology, 2016, 237, 93-115.	1.8	110
237	Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sciences, 1995, 56, 853-859.	4.3	109
238	Alternative mechanisms for tiotropium. Pulmonary Pharmacology and Therapeutics, 2009, 22, 533-542.	2.6	109
239	The Role of Pirenzepine-sensitive (M <sub>1</sub> ) Muscarinic Receptors in Vagally Mediated Bronchoconstriction in Humans. The American Review of Respiratory Disease, 1989, 139, 446-449.	2.9	108
240	Histamine H <sub>3</sub> â€receptors inhibit cholinergic neurotransmission in guineaâ€pig airways. British Journal of Pharmacology, 1989, 97, 13-15.	5.4	108
241	Greater Effect of Inhaled Budesonide on Adenosine 5′-Monophosphate-induced than on Sodium-Metabisulfite-induced Bronchoconstriction in Asthma. The American Review of Respiratory Disease, 1992, 146, 560-564.	2.9	108
242	Cytokine Modulators as Novel Therapies for Asthma. Annual Review of Pharmacology and Toxicology, 2002, 42, 81-98.	9.4	107
243	Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled β2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 270-275.	2.5	107
244	Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-κ B and lack of I-κ B involvement. British Journal of Pharmacology, 1999, 127, 1003-1011.	5.4	106
245	Nasal and Exhaled Nitric Oxide Is Reduced in Adult Patients With Cystic Fibrosis and Does Not Correlate With Cystic Fibrosis Genotype. Chest, 2000, 117, 1085-1089.	0.8	105
246	Emerging Pharmacotherapies for COPD. Chest, 2008, 134, 1278-1286.	0.8	105
247	Faster Rise of Exhaled Breath Temperature in Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 181-184.	5.6	104
248	Sex Differences in Chronic Obstructive Pulmonary Disease Mechanisms. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 813-814.	5.6	104
249	Small Airways in COPD. New England Journal of Medicine, 2004, 350, 2635-2637.	27.0	103
250	Biochemical Basis of Asthma Therapy. Journal of Biological Chemistry, 2011, 286, 32899-32905.	3.4	103
251	A Comparison of <i>β</i> -Adrenergic Receptors and <i>In Vitro</i> Relaxant Responses to Isoproterenol in Asthmatic Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 647-651.	2.9	102
252	Superinduction of COX-2 mRNA by cycloheximide and interleukin-1Î <sup>2</sup> involves increased transcription and correlates with increased NF-Î <sup>9</sup> B and JNK activation. FEBS Letters, 1997, 418, 135-138.	2.8	102

#	Article	IF	CITATIONS
253	Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. European Respiratory Journal, 2001, 17, 1201-1207.	6.7	102
254	Transcription factors in airway diseases. Laboratory Investigation, 2006, 86, 867-872.	3.7	102
255	Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics, 2010, 23, 165-171.	2.6	102
256	Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 398-406.	5.6	101
257	Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. Journal of Allergy and Clinical Immunology, 1997, 99, 58-64.	2.9	100
258	Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet, The, 2000, 355, 1675-1679.	13.7	100
259	Restoration of Corticosteroid Sensitivity by p38 Mitogen Activated Protein Kinase Inhibition in Peripheral Blood Mononuclear Cells from Severe Asthma. PLoS ONE, 2012, 7, e41582.	2.5	100
260	A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF- <i>κ</i> B Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 76-84.	2.5	100
261	Differential Regulation of Cyclo-Oxygenase-1 and Cyclo-Oxygenase-2 Gene Expression by Lipopolysaccharide Treatment in vivo in the Rat. Clinical Science, 1996, 90, 301-306.	4.3	99
262	Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax, 2014, 69, 516-524.	5.6	99
263	The prevalence of small airways disease in adult asthma: A systematic literature review. Respiratory Medicine, 2016, 116, 19-27.	2.9	99
264	Theobromine inhibits sensory nerve activation and cough. FASEB Journal, 2005, 19, 1-16.	0.5	98
265	Inhibition of neurogenic plasma exudation in guineaâ€pig airways by CPâ€96,345, a new nonâ€peptide NK <sub>1</sub> receptor antagonist. British Journal of Pharmacology, 1992, 105, 261-262.	5.4	97
266	Developmental changes in endotheliumâ€dependent pulmonary vasodilatation in pigs. British Journal of Pharmacology, 1992, 106, 324-330.	5.4	97
267	Induction of Phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in Human Peripheral Blood T-lymphocytes by 8-Bromo-cAMP and Gs-coupled Receptor Agonists. Journal of Biological Chemistry, 1998, 273, 20575-20588.	3.4	97
268	Exhaled Nitric Oxide Is Increased in Active Fibrosing Alveolitis. Chest, 1999, 115, 1352-1356.	0.8	97
269	Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2006, 117, 1484-1492.	2.9	97
270	Against the Dutch Hypothesis: Asthma and Chronic Obstructive Pulmonary Disease Are Distinct Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 240-243.	5.6	97

#	Article	IF	CITATIONS
271	Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L279-L289.	2.9	96
272	Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule lκB Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 734-742.	2.5	96
273	Drugs for asthma. British Journal of Pharmacology, 2006, 147, S297-303.	5.4	95
274	Probiotics in the Management of Lung Diseases. Mediators of Inflammation, 2013, 2013, 1-10.	3.0	95
275	Neuropeptides and Asthma. The American Review of Respiratory Disease, 1991, 143, S28-S32.	2.9	94
276	Ozone induction of cytokineâ€induced neutrophil chemoattractant (CINC) and nuclear factorâ€îºb in rat lung: inhibition by corticosteroids. FEBS Letters, 1996, 379, 265-268.	2.8	94
277	Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. Journal of Allergy and Clinical Immunology, 2006, 118, 347-353.	2.9	94
278	Opioid modulation of nonâ€cholinergic neural bronchoconstriction in guineaâ€pig <i>in vivo</i> . British Journal of Pharmacology, 1988, 95, 413-418.	5.4	93
279	Anticholinergic Blockade of Beta-Blocker-induced Bronchoconstriction. The American Review of Respiratory Disease, 1989, 139, 1390-1394.	2.9	93
280	Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. FEBS Journal, 1998, 254, 81-89.	0.2	93
281	New directions in allergic diseases: Mechanism-based anti-inflammatory therapies. Journal of Allergy and Clinical Immunology, 2000, 106, 5-16.	2.9	93
282	Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine and Growth Factor Reviews, 2003, 14, 511-522.	7.2	93
283	Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacological Reviews, 2016, 68, 788-815.	16.0	93
284	IL-1β-dependent activation of NF-κB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Letters, 2003, 547, 75-79.	2.8	92
285	Sensory neuropeptide effects in human skin. British Journal of Pharmacology, 1987, 92, 781-788.	5.4	91
286	Nitric Oxide Synthase Isoenzyme Expression and Activity in Peripheral Lung Tissue of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 21-30.	5.6	91
287	Corticosteroid Inhibition of Airway Microvascular Leakage. The American Review of Respiratory Disease, 1991, 143, 605-609.	2.9	90
288	Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-î± generation. British Journal of Pharmacology, 1997, 122, 149-157.	5.4	90

#	Article	IF	CITATIONS
289	Changes in exhaled carbon monoxide and nitric oxide levels following allergen challenge in patients with asthma. European Respiratory Journal, 1999, 13, 48-52.	6.7	90
290	Brd4 Is Essential for IL-1Î <sup>2</sup> -Induced Inflammation in Human Airway Epithelial Cells. PLoS ONE, 2014, 9, e95051.	2.5	90
291	New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet, The, 2009, 374, 744-755.	13.7	89
292	Passive Smoking Impairs Histone Deacetylase-2 in Children With Severe Asthma. Chest, 2014, 145, 305-312.	0.8	89
293	Exhaled carbon monoxide in childhood asthma. Journal of Pediatrics, 1999, 135, 569-574.	1.8	88
294	Expression of Heme Oxygenase in Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 295-303.	2.9	88
295	Autoradiographic localization of calcitonin gene-related peptide (CGRP) binding sites in human and guinea pig lung. Peptides, 1988, 9, 957-963.	2.4	87
296	Effect of Antiasthma Drugs on Microvascular Leakage in Guinea Pig Airways. The American Review of Respiratory Disease, 1989, 139, 416-421.	2.9	87
297	An inhaled steroid improves markers of airway inflammation in patients with mild asthma. European Respiratory Journal, 1998, 12, 1084-1088.	6.7	87
298	New Therapies for Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 159-166.	5.6	87
299	Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases. European Journal of Pharmacology, 2001, 424, 159-162.	3.5	86
300	Theophylline. Pharmaceuticals, 2010, 3, 725-747.	3.8	86
301	Asthma-COPD Overlap. Chest, 2016, 149, 7-8.	0.8	86
302	Restoration of Corticosteroid Sensitivity in Chronic Obstructive Pulmonary Disease by Inhibition of Mammalian Target of Rapamycin. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 143-153.	5.6	86
303	Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages. European Respiratory Journal, 2019, 54, 1802244.	6.7	86
304	The Action of a Potassium Channel Activator, BRL 38227 (Lemakalim), on Human Airway Smooth Muscle. The American Review of Respiratory Disease, 1990, 142, 1384-1389.	2.9	85
305	Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. European Respiratory Journal, 1997, 10, 1483-1488.	6.7	85
306	Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Current Allergy and Asthma Reports, 2003, 3, 121-129.	5.3	85

#	Article	IF	CITATIONS
307	Bronchodilatory Effect of the PPAR-Î <sup>3</sup> Agonist Rosiglitazone in Smokers With Asthma. Clinical Pharmacology and Therapeutics, 2009, 86, 49-53.	4.7	85
308	Impaired macrophage phagocytosis of bacteria in severe asthma. Respiratory Research, 2014, 15, 72.	3.6	85
309	Neuropeptides in Human Airways: Function and Clinical Implications. The American Review of Respiratory Disease, 1987, 136, S77-S83.	2.9	84
310	Effect of hydrogen peroxide on guineaâ€pig tracheal smooth muscle <i>in vitro</i> : role of cycloâ€oxygenase and airway epithelium. British Journal of Pharmacology, 1989, 98, 325-330.	5.4	84
311	Blunted Perception and Death from Asthma. New England Journal of Medicine, 1994, 330, 1383-1384.	27.0	84
312	Effects of Aerosolized Adenosine 5′-Triphosphate vs Adenosine 5′-Monophosphate on Dyspnea and Airway Caliber in Healthy Nonsmokers and Patients With Asthma. Chest, 2005, 128, 1905-1909.	0.8	84
313	Airway neuropeptides and asthma. Trends in Pharmacological Sciences, 1987, 8, 24-27.	8.7	83
314	Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2 ) receptor activation. British Journal of Pharmacology, 2003, 140, 261-268.	5.4	83
315	Role of GATA-3 in Allergic Diseases. Current Molecular Medicine, 2008, 8, 330-334.	1.3	83
316	Suppression of GATA-3 Nuclear Import and Phosphorylation: A Novel Mechanism of Corticosteroid Action in Allergic Disease. PLoS Medicine, 2009, 6, e1000076.	8.4	83
317	MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology, 2009, 55, 321-331.	2.9	83
318	Calcitonin geneâ€related peptide (CGRP) is a potent nonâ€endotheliumâ€dependent inhibitor of coronary vasomotor tone. British Journal of Pharmacology, 1987, 92, 789-794.	5.4	82
319	Reduction of Nocturnal Asthma by an Inhaled Anticholinergic Drug. Chest, 1986, 90, 485-488.	0.8	81
320	Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Annals of Medicine, 2012, 44, 146-156.	3.8	81
321	ERS/ATS workshop report on respiratory health effects of household air pollution. European Respiratory Journal, 2018, 51, 1700698.	6.7	81
322	μ-opioid receptors modulate non-cholinergic constrictor nerves in guinea-pig airways. European Journal of Pharmacology, 1987, 141, 519-522.	3.5	80
323	The Effects of Activated Eosinophils and Neutrophils on Guinea Pig Airway EpitheliumIn Vitro. American Journal of Respiratory Cell and Molecular Biology, 1990, 2, 341-353.	2.9	80
324	Loop Diuretics Inhibit Cholinergic and Noncholinergic Nerves in Guinea Pig Airways. The American Review of Respiratory Disease, 1991, 143, 1340-1344.	2.9	80

#	Article	IF	CITATIONS
325	The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1β-dependent PGE2 release via mechanistically distinct processes. British Journal of Pharmacology, 2000, 130, 1353-1361.	5.4	80
326	Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. Journal of Applied Physiology, 2003, 95, 2106-2112.	2.5	80
327	Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respiratory Research, 2005, 6, 15.	3.6	80
328	Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activation. Journal of Allergy and Clinical Immunology, 2013, 132, 1075-1085.e6.	2.9	80
329	Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosisâ <sup>*</sup> †âŽThis work was performed at the Catholic University of the Sacred Heart, Rome, Italy, and Ospedale Pediatrico Bambino GesÃ <sup>1</sup> , Rome, Italy. This work was funded by the Catholic University of the Sacred Heart., Free Radical Biology and Medicine, 2008, 45, 913-919.	2.9	79
330	Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury. Clinical Science, 2015, 129, 1011-1023.	4.3	79
331	Bradykininâ€induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate British Journal of Clinical Pharmacology, 1989, 27, 831-836.	2.4	78
332	Neurogenic Inflammation and Asthma. Journal of Asthma, 1992, 29, 165-180.	1.7	78
333	Expression and Regulation of Inducible Nitric Oxide Synthase from Human Primary Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 144-151.	2.9	78
334	Peroxynitrite Elevation in Exhaled Breath Condensate of COPD and Its Inhibition by Fudosteine. Chest, 2009, 135, 1513-1520.	0.8	78
335	Defects of Protein Phosphatase 2A Causes Corticosteroid Insensitivity in Severe Asthma. PLoS ONE, 2011, 6, e27627.	2.5	78
336	Circadian variation in airway function. American Journal of Medicine, 1985, 79, 5-9.	1.5	77
337	The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sciences, 1994, 55, 1147-1153.	4.3	77
338	Nortriptyline Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 465-470.	2.5	77
339	Superinduction of NF-κB by Actinomycin D and Cycloheximide in Epithelial Cells. Biochemical and Biophysical Research Communications, 1996, 218, 518-523.	2.1	76
340	Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. Journal of Allergy and Clinical Immunology, 1998, 101, S427-S433.	2.9	76
341	COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 19, 10-20.	2.3	76
342	Evidence for two platelet activating factor receptors on eosinophils: Dissociation between PAF-induced intracellular calcium mobilization degranulation and superoxides anion generation in eosinophils. Biochemical and Biophysical Research Communications, 1989, 162, 511-521.	2.1	75

#	Article	IF	CITATIONS
343	Questions about inhaled β2-adrenoceptor agonists in asthma. Trends in Pharmacological Sciences, 1992, 13, 20-23.	8.7	75
344	Exhaled 8-isoprostane in childhood asthma. Respiratory Research, 2005, 6, 79.	3.6	75
345	Facilitation by tachykinins of neurotransmission in guineaâ€pig pulmonary parasympathetic nerves. British Journal of Pharmacology, 1989, 97, 274-280.	5.4	74
346	Modulation of nonâ€adrenergic, nonâ€cholinergic neural bronchoconstriction in guineaâ€pig airways via GABA <sub>B</sub> â€receptors. British Journal of Pharmacology, 1989, 97, 1225-1231.	5.4	74
347	Exhaled markers of inflammation. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 217-224.	2.3	73
348	Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. European Journal of Pharmacology, 2001, 429, 327-334.	3.5	73
349	Inhibitors of Protein Kinase C (PKC) Prevent Activated Transcription. Journal of Biological Chemistry, 2004, 279, 18457-18466.	3.4	73
350	Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. British Journal of Pharmacology, 1999, 127, 413-420.	5.4	72
351	Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. European Respiratory Journal, 2001, 18, 466-473.	6.7	72
352	Exhaled Nitric Oxide and Hydrogen Peroxide Concentrations in Asthmatic Smokers. Respiration, 2004, 71, 463-468.	2.6	72
353	Glycopyrrolate Causes Prolonged Bronchoprotection and Bronchodilatation in Patients With Asthma. Chest, 2005, 128, 1974-1979.	0.8	72
354	IL-1β and TNF-α Regulation of the Adenosine Receptor (A2A) Expression: Differential Requirement for NF-κB Binding to the Proximal Promoter. Journal of Immunology, 2006, 177, 7173-7183.	0.8	72
355	Differential Flow Analysis of Exhaled Nitric Oxide in Patients With Asthma of Differing Severity. Chest, 2007, 131, 1353-1362.	0.8	72
356	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	7.1	72
357	Effect of Theophylline and Adenosine on Eosinophil Function. The American Review of Respiratory Disease, 1989, 140, 327-333.	2.9	71
358	Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. British Journal of Pharmacology, 1999, 127, 1151-1158.	5.4	71
359	Glucocorticoids reverse IL-1β-induced impairment of β-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. British Journal of Pharmacology, 2002, 135, 987-996.	5.4	71
360	Validation of the Anti-Inflammatory Properties of Small-Molecule lκB Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle. Molecular Pharmacology, 2006, 70, 697-705.	2.3	71

#	Article	IF	CITATIONS
361	Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD. Chest, 2016, 149, 62-73.	0.8	70
362	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 845-855.	5.6	70
363	Localization of β2-adrenoceptor messenger RNA in human and rat lung using in situ hybridization: correlation with receptor autoradiography. European Journal of Pharmacology, 1991, 206, 133-138.	2.6	69
364	β-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. European Journal of Pharmacology, 1995, 289, 275-281.	2.6	69
365	p38 MAP kinase and MKKâ€1 coâ€operate in the generation of GMâ€CSF from LPSâ€stimulated human monocyte by an NFâ€₽Bâ€independent mechanism. British Journal of Pharmacology, 2000, 131, 1143-1153.	25 5.4	69
366	New Therapies for Chronic Obstructive Pulmonary Disease. Medical Principles and Practice, 2010, 19, 330-338.	2.4	69
367	Interactions of glucocorticoids and beta 2-agonists. European Respiratory Journal, 1996, 9, 160-168.	6.7	68
368	Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma. Chest, 2005, 128, 1936-1942.	0.8	68
369	Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled Î <sup>2</sup> 2 -Agonists in Achieving Asthma Control. Chest, 2008, 134, 1192-1199.	0.8	68
370	Nitric oxide synthase activity is elevated in inflammatory lung disease in humans. European Journal of Pharmacology, 1995, 283, 255-258.	3.5	67
371	Characterization of T Lymphocytes in Chronic Obstructive Pulmonary Disease. PLoS Medicine, 2004, 1, e20.	8.4	67
372	Redox Regulation of Histone Deacetylases and Glucocorticoid-Mediated Inhibition of the Inflammatory Response. Antioxidants and Redox Signaling, 2005, 7, 144-152.	5.4	67
373	Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends in Pharmacological Sciences, 2008, 29, 340-345.	8.7	67
374	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1548.	7.4	67
375	Pathophysiology and clinical presentations of coughâ~†â~†â~†â~ Journal of Allergy and Clinical Immunology, 1996, 98, S91-S97.	2.9	66
376	p38 Mitogen-Activated Protein Kinase-γ Inhibition by Long-Acting β2 Adrenergic Agonists Reversed Steroid Insensitivity in Severe Asthma. Molecular Pharmacology, 2011, 80, 1128-1135.	2.3	66
377	Cholinergic Control of Airway Smooth Muscle. The American Review of Respiratory Disease, 1987, 136, S42-S45.	2.9	65
378	Comparison of neurokinin A and substance P on cardiovascular and airway function in man British Journal of Clinical Pharmacology, 1988, 25, 273-275.	2.4	65

#	Article	IF	CITATIONS
379	Cytokine-directed therapies for asthmaâ~†â~†â~†. Journal of Allergy and Clinical Immunology, 2001, 108, S72-S76.	2.9	65
380	Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities. Proceedings of the American Thoracic Society, 2008, 5, 857-864.	3.5	65
381	Hydrogen Peroxide in Exhaled Breath Condensate in Patients with Asthma. Chest, 2011, 140, 108-116.	0.8	64
382	Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respiratory Research, 2013, 14, 137.	3.6	64
383	MicroRNAâ€570 is a novel regulator of cellular senescence and inflammaging. FASEB Journal, 2019, 33, 1605-1616.	0.5	64
384	Circulatory and respiratory effects of infused adenosine in conscious man British Journal of Clinical Pharmacology, 1987, 24, 306-317.	2.4	63
385	Effect of CP-96,345, a non-peptide NK1 receptor antagonist, against substance P-, bradykinin- and allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig. European Journal of Pharmacology, 1993, 231, 31-38.	3.5	63
386	Effect of inhaled corticosteroids on bones and growth. European Respiratory Journal, 1998, 11, 1167-1177.	6.7	63
387	Different Mitogen-Activated Protein Kinase-Dependent Cytokine Responses in Cells of the Monocyte Lineage. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 306-312.	2.5	63
388	A comprehensive analysis of oxidative stress in the ozone-induced lung inflammation mouse model. Clinical Science, 2014, 126, 425-440.	4.3	63
389	Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. European Respiratory Journal, 2017, 49, 1602006.	6.7	63
390	Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respiratory Research, 2014, 15, 114.	3.6	62
391	Microarray analysis of long non-coding RNAs in COPD lung tissue. Inflammation Research, 2015, 64, 119-126.	4.0	62
392	Radioligand binding of antagonists of platelet-activating factor to intact human platelets. FEBS Letters, 1988, 228, 285-289.	2.8	61
393	Modulation of cholinergic neurotransmission in guineaâ€pig trachea by neuropeptide Y. British Journal of Pharmacology, 1988, 93, 672-678.	5.4	61
394	Current Therapies for Asthma. Chest, 1997, 111, 17S-26S.	0.8	61
395	Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. BMC Pulmonary Medicine, 2013, 13, 43.	2.0	61
396	Bromodomain and Extraterminal Proteins Suppress NF-E2–Related Factor 2–Mediated Antioxidant Gene Expression. Journal of Immunology, 2014, 192, 4913-4920.	0.8	61

#	Article	IF	CITATIONS
397	Is Immunotherapy for Asthma Worthwhile?. New England Journal of Medicine, 1996, 334, 531-532.	27.0	60
398	Small airway fibrosis in COPD. International Journal of Biochemistry and Cell Biology, 2019, 116, 105598.	2.8	60
399	The effect of platelet activating factor on pulmonary βâ€adrenoceptors. British Journal of Pharmacology, 1987, 90, 709-715.	5.4	59
400	Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated With Increased Sputum Interleukin-8 and Neutrophils. Chest, 2007, 132, 98-105.	0.8	59
401	The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. Journal of Allergy and Clinical Immunology, 2011, 128, 800-807.e9.	2.9	59
402	New perspectives in pharmacological treatment of mild persistent asthma. Drug Discovery Today, 2011, 16, 1084-1091.	6.4	59
403	Effect of interleukin-1β on airway hyperresponsiveness and inflammation in sensitized and nonsensitized Brown-Norway rats. Journal of Allergy and Clinical Immunology, 1994, 93, 464-469.	2.9	58
404	Autoradiographic mapping of beta-adrenoceptors in human skin. Archives of Dermatological Research, 1996, 288, 549-553.	1.9	58
405	Effects of Corticosteroids on Noninvasive Biomarkers of Inflammation in Asthma and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2004, 1, 191-199.	3.5	58
406	Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. European Journal of Pharmacology, 2011, 670, 244-251.	3.5	57
407	Glucocorticoids. Chemical Immunology and Allergy, 2014, 100, 311-316.	1.7	57
408	Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease. Respiratory Research, 2020, 21, 50.	3.6	57
409	Epithelial Mediators. The American Review of Respiratory Disease, 1987, 136, S32-S35.	2.9	56
410	Endogenous tachykinins facilitate transmission through parasympathetic ganglia in guineaâ€pig trachea. British Journal of Pharmacology, 1993, 109, 751-759.	5.4	56
411	Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroidâ€independent mechanism. British Journal of Pharmacology, 2017, 174, 2043-2059.	5.4	56
412	Mitochondrial dysfunction in lung ageing and disease. European Respiratory Review, 2020, 29, 200165.	7.1	56
413	Corticosteroids, IgE, and atopy. Journal of Clinical Investigation, 2001, 107, 265-266.	8.2	56
414	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. European Respiratory Journal, 2022, 60, 2102951.	6.7	56

#	Article	IF	CITATIONS
415	Chairman's Summary. The American Review of Respiratory Disease, 1990, 141, S97-S98.	2.9	55
416	Alternate COX-2 Transcripts Are Differentially Regulated: Implications for Post-Transcriptional Control. Biochemical and Biophysical Research Communications, 1997, 234, 85-89.	2.1	55
417	Inducible nitric oxide synthase after sensitization and allergen challenge of Brown Norway rat lung. British Journal of Pharmacology, 1997, 121, 1241-1246.	5.4	55
418	Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respiratory Research, 2004, 5, 17.	3.6	55
419	Corticosteroid insensitivity is reversed by formoterol via phosphoinositideâ€3â€kinase inhibition. British Journal of Pharmacology, 2012, 167, 775-786.	5.4	55
420	Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guineaâ€pigs <i>in vivo</i> . British Journal of Pharmacology, 1993, 108, 844-851.	5.4	54
421	Molecular Regulation of Granulocyte Macrophage Colony-Stimulating Factor in Human Lung Epithelial Cells by Interleukin (IL)-1 Î <sup>2</sup> , IL-4, and IL-13 Involves Both Transcriptional and Post-Transcriptional Mechanisms. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 582-589	2.9	54
422	COPD—a neglected disease. Lancet, The, 2004, 364, 564-565.	13.7	54
423	Inflammation, Oxidative Stress and Systemic Effects in Mild Chronic Obstructive Pulmonary Disease. International Journal of Immunopathology and Pharmacology, 2007, 20, 753-763.	2.1	54
424	Oxidative Stress in Chronic Obstructive Pulmonary Disease. Antioxidants, 2022, 11, 965.	5.1	54
425	Inhibitory role of endothelium-derived relaxing factor in rat and human pulmonary arteries. British Journal of Pharmacology, 1990, 101, 166-170.	5.4	53
426	Role of nitric oxide and guanosine 3′,5′ yclic monophosphate in mediating nonadrenergic, noncholinergic relaxation in guineaâ€pig pulmonary arteries. British Journal of Pharmacology, 1992, 107, 861-866.	5.4	53
427	Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-î± generation from human peripheral blood monocytes. Cell Biochemistry and Biophysics, 1998, 29, 179-201.	1.8	53
428	Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. Chest, 2015, 148, 1164-1176.	0.8	53
429	Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. European Respiratory Journal, 2016, 47, 1093-1102.	6.7	53
430	Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs of Today, 2002, 38, 585.	2.4	53
431	Bradykininâ€induced plasma exudation in guineaâ€pig airways: involvement of platelet activating factor. British Journal of Pharmacology, 1990, 101, 739-745.	5.4	52
432	Responses of Leukocytes to Chemokines in Whole Blood and Their Antagonism by Novel CC-Chemokine Receptor 3 Antagonists. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1602-1609.	5.6	52

#	Article	IF	CITATIONS
433	Novel signal transduction modulators for the treatment of airway diseases. , 2006, 109, 238-245.		52
434	Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease. Clinical Science, 2017, 131, 1147-1159.	4.3	52
435	Endogenous nitric oxide modulates adrenergic neural vasoconstriction in guineaâ€pig pulmonary artery. British Journal of Pharmacology, 1991, 104, 565-569.	5.4	51
436	Actions of methoctramine, a muscarinic M <sub>2</sub> receptor antagonist, on muscarinic and nicotinic cholinoceptors in guineaâ€pig airways <i>in vivo</i> and <i>in vitro</i> . British Journal of Pharmacology, 1992, 105, 107-112.	5.4	51
437	The role of anticholinergics in chronic obstructive pulmonary disease. The American Journal of Medicine: Supplement, 2004, 117, 24-32.	1.6	51
438	Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2014, 133, 207-216.e11.	2.9	51
439	Decreased Serum Sirtuin-1 in COPD. Chest, 2017, 152, 343-352.	0.8	51
440	The effect of alcohol ingestion on exhaled nitric oxide. European Respiratory Journal, 1996, 9, 1130-1133.	6.7	50
441	Attenuated Production of Intracellular IL-10 and IL-12 in Monocytes from Patients with Severe Asthma. Clinical Immunology, 2002, 102, 258-266.	3.2	50
442	Importinâ€7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. FASEB Journal, 2013, 27, 4510-4519.	0.5	50
443	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD. Chest, 2016, 150, 123-130.	0.8	50
444	Is Asthma a Nervous Disease?. Chest, 1995, 107, 119S-125S.	0.8	49
445	Regulation of eosinophil apoptosis by nitric oxide: Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. Journal of Allergy and Clinical Immunology, 2003, 112, 93-101.	2.9	49
446	New therapies for asthma. Trends in Molecular Medicine, 2006, 12, 515-520.	6.7	49
447	Oxidative stress modulates theophylline effects on steroid responsiveness. Biochemical and Biophysical Research Communications, 2008, 377, 797-802.	2.1	49
448	Hypoxia-inducible Factor 1α Induces Corticosteroid-insensitive Inflammation via Reduction of Histone Deacetylase-2 Transcription. Journal of Biological Chemistry, 2009, 284, 36047-36054.	3.4	49
449	Exhaled carbon monoxide in asthmatics: a meta-analysis. Respiratory Research, 2010, 11, 50.	3.6	49
450	Dilemmas, Confusion, and Misconceptions Related to Small Airways Directed Therapy. Chest, 2017, 151, 1345-1355.	0.8	49

#	Article	IF	CITATIONS
451	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. PLoS ONE, 2016, 11, e0163139.	2.5	49
452	Nitric Oxide Metabolites Are Not Reduced in Exhaled Breath Condensate of Patients With Primary Ciliary Dyskinesia*. Chest, 2003, 124, 633-638.	0.8	48
453	Effects of Aminoguanidine, an Inhibitor of Inducible Nitric Oxide Synthase, on Nitric Oxide Production and Its Metabolites in Healthy Control Subjects, Healthy Smokers, and COPD Patients. Chest, 2009, 135, 353-367.	0.8	48
454	Toll-like Receptor 3 Stimulation Causes Corticosteroid-Refractory Airway Neutrophilia and Hyperresponsiveness in Mice. Chest, 2013, 144, 99-105.	0.8	48
455	Effect of tachykinins in small human airways. Neuropeptides, 1991, 19, 157-161.	2.2	47
456	Modulation of airway smooth muscle β-adrenoceptor function by a muscarinic agonist. Life Sciences, 1994, 54, 185-191.	4.3	47
457	Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 2008, 121, 43-50.	2.9	47
458	Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. Journal of Allergy and Clinical Immunology, 2013, 132, 1166-1173.	2.9	47
459	Sputum myeloperoxidase in chronic obstructive pulmonary disease. European Journal of Medical Research, 2014, 19, 12.	2.2	47
460	Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L230-L239.	2.9	47
461	Tumour Necrosis Factor-α Regulates Human Eosinophil Apoptosis via Ligation of TNF-Receptor 1 and Balance between NF-κB and AP-1. PLoS ONE, 2014, 9, e90298.	2.5	47
462	Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography. British Journal of Pharmacology, 1986, 89, 157-162.	5.4	46
463	Regulation of NANC neural bronchoconstriction <i>in vivo</i> in the guineaâ€pig: involvement of nitric oxide, vasoactive intestinal peptide and soluble guanylyl cyclase. British Journal of Pharmacology, 1993, 108, 228-235.	5.4	46
464	Effects of dexamethasone on cytokine and phorbol ester stimulated c-Fos and c-Jun DNA binding and gene expression in human lung. European Respiratory Journal, 1994, 7, 2117-2123.	6.7	46
465	Adding formoterol to budesonide in moderate asthma—health economic results from the FACET study. Respiratory Medicine, 2001, 95, 505-512.	2.9	46
466	Does Exhaled Nitric Oxide Reflect Asthma Control?. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 727-728.	5.6	46
467	ICAMâ€∎ expression is highly NFâ€ÎºBâ€dependent in A549 cells. FEBS Journal, 2004, 271, 785-791.	0.2	46
468	Prevention of Death in COPD. New England Journal of Medicine, 2007, 356, 2211-2214.	27.0	46

#	Article	IF	CITATIONS
469	Frontrunners in novel pharmacotherapy of COPD. Current Opinion in Pharmacology, 2008, 8, 300-307.	3.5	46
470	Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. Thorax, 2013, 68, 330-337.	5.6	46
471	Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine,the, 2021, 9, 149-158.	10.7	46
472	Biochemistry of asthma. Trends in Biochemical Sciences, 1991, 16, 365-369.	7.5	45
473	Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opinion on Therapeutic Targets, 2005, 9, 1111-1121.	3.4	45
474	Chronic Obstructive Pulmonary Disease and Lung Cancer: A Lethal Association. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 866-867.	5.6	45
475	Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. Journal of Allergy and Clinical Immunology, 2019, 144, 1180-1186.	2.9	45
476	Receptor heterodimerization: a new level of cross-talk. Journal of Clinical Investigation, 2006, 116, 1210-1212.	8.2	45
477	Therapy of chronic obstructive pulmonary disease. , 2003, 97, 87-94.		44
478	Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E2 release. FEBS Journal, 2004, 271, 4042-4052.	0.2	44
479	Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells. PLoS ONE, 2015, 10, e0128757.	2.5	44
480	Senotherapy. Chest, 2020, 158, 562-570.	0.8	44
481	Posture and theophylline kinetics British Journal of Clinical Pharmacology, 1985, 19, 707-709.	2.4	43
482	The Effect of Platelet-activating Factor on Histamine and Muscarinic Receptor Function in Guinea Pig Airways. The American Review of Respiratory Disease, 1988, 137, 1317-1322.	2.9	43
483	Evidence for two P <sub>2</sub> â€purinoceptor subtypes in human small pulmonary arteries. British Journal of Pharmacology, 1989, 98, 1014-1020.	5.4	43
484	Inhibitory cytokines in asthma. Trends in Molecular Medicine, 1998, 4, 452-458.	2.6	43
485	Tiotropium bromide. Expert Opinion on Investigational Drugs, 2001, 10, 733-740.	4.1	43
486	The Role of ll̂ºB Kinase 2, but Not Activation of NF-l̂ºB, in the Release of CXCR3 Ligands from IFN-l̂3-Stimulated Human Bronchial Epithelial Cells. Journal of Immunology, 2007, 179, 6237-6245.	0.8	43

#	Article	IF	CITATIONS
487	Increased corticosteroid sensitivity by a long acting β2 agonist formoterol via β2 adrenoceptor independent protein phosphatase 2A activation. Pulmonary Pharmacology and Therapeutics, 2012, 25, 201-207.	2.6	43
488	TGF-β Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD. Chest, 2018, 153, 851-862.	0.8	43
489	PAF Antagonists. Drugs, 1988, 35, 93-103.	10.9	42
490	Characterization of platelet-activating factor-induced elevation of cytosolic free calcium concentration in eosinophils. FEBS Letters, 1989, 243, 41-46.	2.8	42
491	Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(—)-rolipram binding by selective inhibitors. Biochemical Journal, 1996, 318, 425-436.	3.7	42
492	Anti-IgE Therapy in Asthma: Rationale and Therapeutic Potential. International Archives of Allergy and Immunology, 2000, 123, 196-204.	2.1	42
493	Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. European Journal of Pharmacology, 2002, 436, 165-172.	3.5	42
494	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. British Journal of Pharmacology, 2002, 136, 620-628.	5.4	42
495	Glucocorticoid Inhibition of Granulocyte Macrophage–Colony-Stimulating Factor from T cells Is Independent of Control by Nuclear Factor-κB and Conserved Lymphokine Element 0. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 555-563.	2.9	42
496	Achieving asthma control. Current Medical Research and Opinion, 2005, 21, S5-S9.	1.9	42
497	Unexpected Failure of Anti–Tumor Necrosis Factor Therapy in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 866-867.	5.6	41
498	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. European Respiratory Review, 2018, 27, 180010.	7.1	41
499	The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects British Journal of Clinical Pharmacology, 1987, 23, 91-93.	2.4	40
500	Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guineaâ€pig and platelet aggregation in man. British Journal of Pharmacology, 1988, 94, 164-168.	5.4	40
501	Evidence that the anti-spasmogenic effect of the Î <sup>2</sup> -adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase. British Journal of Pharmacology, 2001, 133, 1201-1212.	5.4	40
502	Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. European Respiratory Journal, 2003, 22, 457-461.	6.7	40
503	Effect of an Inducible Nitric Oxide Synthase Inhibitor on Differential Flow-Exhaled Nitric Oxide in Asthmatic Patients and Healthy Volunteers. Chest, 2007, 132, 581-588.	0.8	40
504	Effect of infused adenosine on cardiac output and systemic resistance in normal subjects British Journal of Clinical Pharmacology, 1989, 27, 165-171.	2.4	39

#	Article	IF	CITATIONS
505	Contribution of Intercellular-Adhesion Molecule-1 in Allergen-Induced Airway Hyperresponsiveness and Inflammation in Sensitised Brown-Norway Rats. International Archives of Allergy and Immunology, 1994, 104, 291-295.	2.1	39
506	Transcriptional Down-regulation of m2 Muscarinic Receptor Gene Expression in Human Embryonic Lung (HEL 299) Cells by Protein Kinase C. Journal of Biological Chemistry, 1995, 270, 7213-7218.	3.4	39
507	Cyclic AMPâ€elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GMâ€CSF. British Journal of Pharmacology, 1996, 117, 79-86.	5.4	39
508	Mitogen-Activated Protein Kinase Modulation of Nuclear Factor-κB–Induced Granulocyte Macrophage–Colony-Stimulating Factor Release from Human Alveolar Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 342-349.	2.9	39
509	Validation of IKKβ as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKKβ to pulmonary epithelial cells. British Journal of Pharmacology, 2005, 145, 114-122.	5.4	39
510	Rapid Effect of Inhaled Ciclesonide in Asthma. Chest, 2008, 134, 740-745.	0.8	39
511	Regulation of IL-17 in chronic inflammation in the human lung. Clinical Science, 2011, 120, 515-524.	4.3	39
512	Sputum Plasminogen Activator Inhibitor-1 Elevation by Oxidative Stress-Dependent Nuclear Factor-κB Activation in COPD. Chest, 2013, 144, 515-521.	0.8	39
513	Theophylline: Mechanism of action and use in asthma and chronic obstructive pulmonary disease. Drugs of Today, 2004, 40, 55.	2.4	39
514	Effect of a PAF antagonist, BN52063, on PAFâ€induced bronchoconstriction in normal subjects British Journal of Clinical Pharmacology, 1988, 26, 65-72.	2.4	38
515	Long-acting β2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?. Current Opinion in Pharmacology, 2003, 3, 270-276.	3.5	38
516	Mitogen-activated protein kinases mediate peroxynitrite-induced cell death in human bronchial epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L1112-L1120.	2.9	38
517	PAF closely mimics pathology of asthma. Trends in Pharmacological Sciences, 1987, 8, 285-287.	8.7	37
518	Stimulus-Specific Inhibition of IL-5 by cAMP-Elevating Agents and IL-10 Reveals Differential Mechanisms of Action. Biochemical and Biophysical Research Communications, 2000, 273, 811-815.	2.1	37
519	The problem of cough and development of novel antitussives. Pulmonary Pharmacology and Therapeutics, 2007, 20, 416-422.	2.6	37
520	A Novel Approach to Partition Central and Peripheral Airway Nitric Oxide. Chest, 2014, 145, 113-119.	0.8	37
521	Extracellular Adenosine 5'-Triphosphate inÂObstructive Airway Diseases. Chest, 2016, 150, 908-915.	0.8	37
522	Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. Biochemical Pharmacology, 1991, 42, 663-677.	4.4	36

#	Article	IF	CITATIONS
523	COPD: is there light at the end of the tunnel?. Current Opinion in Pharmacology, 2004, 4, 263-272.	3.5	36
524	Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite–sensitive patients with asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 239-248.	2.9	36
525	Rescue Treatment in Asthma. Chest, 2009, 135, 1628-1633.	0.8	36
526	Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2016, 137, 1595-1597.e7.	2.9	36
527	Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 665-668.	5.6	36
528	Inflammatory mechanisms and nocturnal asthma. American Journal of Medicine, 1988, 85, 64-70.	1.5	35
529	Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 445-453.	2.9	35
530	Ezrin, a Membrane Cytoskeleton Cross-Linker Protein, as a Marker of Epithelial Damage in Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 496-507.	5.6	35
531	Inhaled glucocorticoids: new developments relevant to updating of the Asthma Management Guidelines. Respiratory Medicine, 1996, 90, 379-384.	2.9	34
532	Pleiotropic role of lyn kinase in leukotriene B4–induced eosinophil activation. Blood, 2000, 95, 3541-3547.	1.4	34
533	Ceramide Induction of COX-2 and PGE2 in Pulmonary A549 Cells Does Not Involve Activation of NF-κB. Biochemical and Biophysical Research Communications, 2000, 277, 675-679.	2.1	34
534	Corticosteroids. Clinics in Chest Medicine, 2012, 33, 531-541.	2.1	34
535	Glucocorticosteroids: current and future directions. British Journal of Pharmacology, 2011, 163, 29-43.	5.4	34
536	Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea <i>in vitro</i> . British Journal of Pharmacology, 1996, 118, 998-1002.	5.4	33
537	Transforming growth factor-β 1 inhibits β 2 -adrenoceptor gene transcription. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 362, 520-525.	3.0	33
538	The burden of exacerbations in mild asthma: a systematic review. ERJ Open Research, 2020, 6, 00359-2019.	2.6	33
539	THE CHRONOPHARMACOLOGY AND CHRONOTHERAPY OF ASTHMA. , 1986, , 229-273.		32
540	Prostaglandin E2 suppression of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by interacting with prostanoid receptors of the EP3 -subtype. British Journal of Pharmacology, 1998, 123, 1246-1252.	5.4	32

#	Article	IF	CITATIONS
541	The size of the problem of managing asthma. Respiratory Medicine, 2004, 98, S4-S8.	2.9	32
542	Regulation of Wnt4 in chronic obstructive pulmonary disease. FASEB Journal, 2013, 27, 2367-2381.	0.5	32
543	COPD 2020: new directions needed. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L884-L886.	2.9	32
544	Tumour Necrosis Factor α Causes Retention of Activated Glucocorticoid Receptor within the Cytoplasm of A549 Cells. Biochemical and Biophysical Research Communications, 1996, 225, 545-550.	2.1	31
545	Glucocorticoids reduce tachykinin NK2 receptor expression in bovine tracheal smooth muscle. European Journal of Pharmacology, 1998, 344, 99-106.	3.5	31
546	Current and Future Therapies for Airway Mucus Hypersecretion. Novartis Foundation Symposium, 2008, , 237-253.	1.1	31
547	Sarcoidosis: Role of non-tuberculosis mycobacteria and Mycobacterium tuberculosis. International Journal of Mycobacteriology, 2014, 3, 225-229.	0.6	31
548	Anti-IgE Antibody Therapy for Asthma. New England Journal of Medicine, 1999, 341, 2006-2008.	27.0	30
549	Chronic systemic administration of salmeterol to rats promotes pulmonary β2 -adrenoceptor desensitization and down-regulation of Gsα. British Journal of Pharmacology, 2001, 132, 1261-1270.	5.4	30
550	Defect of Adaptation to Hypoxia in Patients With COPD Due to Reduction of Histone Deacetylase 7. Chest, 2012, 141, 1233-1242.	0.8	30
551	Quercetin restores corticosteroid sensitivity in cells from patients with chronic obstructive pulmonary disease. Experimental Lung Research, 2017, 43, 417-425.	1.2	30
552	Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. European Respiratory Journal, 2019, 53, 1702273.	6.7	30
553	The evolving algorithm of biological selection in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1555-1563.	5.7	30
554	Measurement of 8-Isoprostane in Exhaled Breath Condensate. Methods in Molecular Biology, 2010, 594, 73-84.	0.9	30
555	Development of New Drugs for COPD. Current Medicinal Chemistry, 2013, 20, 1531-1540.	2.4	30
556	Priming of circulating human eosinophils following late response to allergen challenge. European Respiratory Journal, 1996, 9, 703-708.	6.7	29
557	Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease. European Respiratory Journal, 2003, 21, 439-443.	6.7	29
558	Treatment with (R)-Albuterol Has No Advantage over Racemic Albuterol. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 969-972.	5.6	29

#	Article	IF	CITATIONS
559	Corticosteroid modulation of immunoglobulin expression and Bâ€cell function in COPD. FASEB Journal, 2016, 30, 2014-2026.	0.5	29
560	Pulmonary Diseases and Ageing. Sub-Cellular Biochemistry, 2019, 91, 45-74.	2.4	29
561	Platelet-activating factor-induced enhancement of superoxide anion generation in guinea-pigs. European Journal of Pharmacology, 1993, 232, 7-12.	3.5	28
562	High affinity [3H]formoterol binding sites in lung: characterization and autoradiographic mapping. European Journal of Pharmacology, 1994, 269, 35-41.	2.6	28
563	Nitric oxide and asthma. Research in Immunology, 1995, 146, 698-702.	0.9	28
564	Protein kinase C isoenzymes in airway smooth muscle. Biochemical Journal, 1997, 324, 167-175.	3.7	28
565	Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate. Disease Markers, 2011, 30, 213-220.	1.3	28
566	Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 508-522.	2.1	28
567	Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative. Frontiers in Pharmacology, 2018, 9, 753.	3.5	28
568	Phosphoinositide Turnover. The American Review of Respiratory Disease, 1987, 136, S17-S20.	2.9	27
569	Lack of effect of zaprinast on methacholineâ€induced contraction and inositol 1,4,5â€trisphosphate accumulation in bovine tracheal smooth muscle. British Journal of Pharmacology, 1991, 103, 1119-1125.	5.4	27
570	Molecular Mechanisms of Antiasthma Therapy. Annals of Medicine, 1995, 27, 531-535.	3.8	27
571	Dexamethasone inhibits ozone-induced gene expression of macrophage inflammatory protein-2 in rat lung. FEBS Letters, 1995, 363, 285-288.	2.8	27
572	β2-Adrenoceptor Agonist-Induced Upregulation of Tachykinin NK2Receptor Expression and Function in Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 409-417.	2.9	27
573	Novel drugs for treating asthma. Current Allergy and Asthma Reports, 2001, 1, 164-173.	5.3	27
574	Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma. Chest, 2002, 121, 1401-1406.	0.8	27
575	Inhaled Aerosol Distribution in Human Airways: A Scintigraphy-Guided Study in a 3D Printed Model. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 525-533.	1.4	27
576	A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1378-1387.e5.	3.8	27

#	Article	IF	CITATIONS
577	Pharmacology of airways and vessels in lung slices in situ: role of endogenous dilator hormones. Respiratory Research, 2006, 7, 111.	3.6	26
578	Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ: British Medical Journal, 2007, 335, 513-513.	2.3	26
579	Optimized Dialysis and Protease Inhibition of Sputum Dithiothreitol Supernatants. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 132-141.	5.6	26
580	A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways. European Journal of Pharmacology, 2013, 702, 109-115.	3.5	26
581	Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology, 2015, 79, 492-500.	2.4	26
582	Low BMI and weight loss aggravate COPD mortality in men, findings from a large prospective cohort: the JACC study. Scientific Reports, 2021, 11, 1531.	3.3	26
583	Epigenetics and chromatin remodeling play a role in lung disease. Tanaffos, 2011, 10, 7-16.	0.5	26
584	Cytokine modulators for allergic diseases. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 555-560.	2.3	25
585	Looking for Airways Periostin in Severe Asthma. Chest, 2018, 154, 1083-1090.	0.8	25
586	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. Frontiers in Pharmacology, 2018, 9, 258.	3.5	25
587	Our changing understanding of asthma. Respiratory Medicine, 1989, 83, 17-23.	2.9	24
588	Effects of aerosolised substance P on lung resistance in guineaâ€pigs: a comparison between inhibition of neutral endopeptidase and angiotensinâ€converting enzyme. British Journal of Pharmacology, 1990, 100, 69-72.	5.4	24
589	A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. International Journal of Pharmaceutics, 2003, 254, 243-253.	5.2	24
590	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial. European Respiratory Journal, 2021, 57, 2003338.	6.7	24
591	Cholecystokininâ€octapeptide constricts guineaâ€pig and human airways. British Journal of Pharmacology, 1989, 97, 675-682.	5.4	23
592	Purinoceptors in the pulmonary circulation of the rat and their role in hypoxic vasoconstriction. British Journal of Pharmacology, 1989, 98, 367-372.	5.4	23
593	Involvement of inflammatory mediators in the airway responses to trimellitic anhydride in sensitized guineaâ€pigs. British Journal of Pharmacology, 1992, 106, 828-832.	5.4	23
594	Attenuation of tachykininâ€induced airflow obstruction and microvascular leakage in immature airways. British Journal of Pharmacology, 1993, 108, 23-29.	5.4	23

#	Article	IF	CITATIONS
595	Adenosine 5′-monophosphate increases levels of leukotrienes in breath condensate in asthma. Respiratory Medicine, 2004, 98, 651-655.	2.9	23
596	Neutrophils Find Smoke Attractive. Science, 2010, 330, 40-41.	12.6	23
597	Club Cells, Their Secretory Protein, and COPD. Chest, 2015, 147, 1447-1448.	0.8	23
598	Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. Respiratory Research, 2016, 17, 104.	3.6	23
599	Pathogenesis of COPD and Asthma. Handbook of Experimental Pharmacology, 2016, 237, 1-21.	1.8	23
600	Validation of the Exhaled Breath Temperature Measure. Chest, 2017, 151, 855-860.	0.8	23
601	Involvement of hydroxyl radicals in neurogenic airway plasma exudation and bronchoconstriction in guineaâ€pigs <i>in vivo</i> . British Journal of Pharmacology, 1996, 117, 449-454.	5.4	22
602	Reduced HDAC2 in skeletal muscle of COPD patients. Respiratory Research, 2017, 18, 99.	3.6	22
603	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3069-3077.e6.	3.8	22
604	Neuropeptides and airway smooth muscle. , 1988, 36, 119-129.		21
605	Pharmacological modulation of inhaled sodium metabisulphiteâ€induced airway microvascular leakage and bronchoconstriction in the guineaâ€pig. British Journal of Pharmacology, 1992, 107, 481-487.	5.4	21
606	Effect of maturation on histamine-induced airflow obstruction and airway microvascular leakage in guinea pig airways. European Journal of Pharmacology, 1992, 215, 51-56.	3.5	21
607	Triple inhalers for obstructive airways disease: will they be useful?. Expert Review of Respiratory Medicine, 2011, 5, 297-300.	2.5	21
608	Similarities and differences in inflammatory mechanisms of asthma and COPD. Breathe, 2011, 7, 229-238.	1.3	21
609	New Drugs for Asthma. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 685-694.	2.1	21
610	Glycogen synthase kinase-3β modulation of glucocorticoid responsiveness in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1112-L1123.	2.9	21
611	Activation of Transcription Factor Nrf2 Signalling by the Sphingosine Kinase Inhibitor SKI-II Is Mediated by the Formation of Keap1 Dimers. PLoS ONE, 2014, 9, e88168.	2.5	21
612	Neural control of airway function: New perspectives. Molecular Aspects of Medicine, 1990, 11, 351-423.	6.4	20

#	Article	IF	CITATIONS
613	Novel therapy for asthma. Expert Opinion on Investigational Drugs, 2000, 9, 25-42.	4.1	20
614	GM-CSF Expression in Pulmonary Epithelial Cells Is Regulated Negatively by Posttranscriptional Mechanisms. Biochemical and Biophysical Research Communications, 2001, 287, 249-253.	2.1	20
615	The role of inflammation and anti-inflammatory medication in asthma. Respiratory Medicine, 2002, 96, S9-S15.	2.9	20
616	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 2015, 16, 267.	1.6	20
617	The effect of body weight on distal airway function and airway inflammation. Obesity Research and Clinical Practice, 2016, 10, 564-573.	1.8	20
618	Endo-phenotyping of COPD patients. Expert Review of Respiratory Medicine, 2021, 15, 27-37.	2.5	20
619	Autophagy in asthma and chronic obstructive pulmonary disease. Clinical Science, 2022, 136, 733-746.	4.3	20
620	Effect of 8-iso-prostaglandin F2α on acetylcholine release from parasympathetic nerves in guinea pig airways. European Journal of Pharmacology, 2001, 416, 231-234.	3.5	19
621	Anti-leukotrienes: here to stay?. Current Opinion in Pharmacology, 2003, 3, 257-263.	3.5	19
622	Inflammatory Response to Sputum Induction Measured by Exhaled Markers. Respiration, 2005, 72, 594-599.	2.6	19
623	Expression of nonmuscle cofilin-1 and steroid responsiveness in severe asthma. Journal of Allergy and Clinical Immunology, 2006, 118, 1090-1096.	2.9	19
624	Activation of NFâ€₽̂B transcription factor in asthma death. Histopathology, 2009, 54, 507-509.	2.9	19
625	Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD. European Respiratory Journal, 2014, 43, 1504-1506.	6.7	19
626	Effect of 5-HTA receptor agonist, 8-OH-DPAT, on cough responses in the conscious guinea-pig. European Journal of Pharmacology, 1997, 332, 201-207.	3.5	18
627	Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma. European Respiratory Journal, 1999, 14, 1023-1027.	6.7	18
628	Clinical outcome of adding long-acting Î <sup>2</sup> -agonists to inhaled corticosteroids. Respiratory Medicine, 2001, 95, S12-S16.	2.9	18
629	5-Azacytidine suppresses RNA polymerase II recruitment to the SLPI gene. Biochemical and Biophysical Research Communications, 2005, 331, 93-99.	2.1	18
630	Potential Novel Therapies for Chronic Obstructive Pulmonary Disease. Novartis Foundation Symposium, 2008, , 255-272.	1.1	18

#	Article	IF	CITATIONS
631	Smoking Cessation in COPD Causes a Transient Improvement in Spirometry and Decreases Micronodules on High-Resolution CT Imaging. Chest, 2014, 145, 1006-1015.	0.8	18
632	Cigarette smoke-induced impairment of autophagy in macrophages increases galectin-8 and inflammation. Scientific Reports, 2021, 11, 335.	3.3	18
633	Effect of an inhaled histamine H3â€receptor agonist on airway responses to sodium metabisulphite in asthma British Journal of Clinical Pharmacology, 1993, 35, 55-57.	2.4	17
634	Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone. Immunology, 2003, 109, 527-535.	4.4	17
635	Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy and Asthma Proceedings, 2012, 33, 140-144.	2.2	17
636	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulmonary Medicine, 2014, 14, 166.	2.0	17
637	Glottal Aperture and Buccal Airflow Leaks Critically Affect Forced Oscillometry Measurements. Chest, 2015, 148, 731-738.	0.8	17
638	Chronic Obstructive Pulmonary Disease Endotypes in Low- and Middle-Income Country Settings: Precision Medicine for All. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 171-172.	5.6	17
639	Positioning As-needed Budesonide–Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. Annals of the American Thoracic Society, 2021, 18, 2007-2017.	3.2	17
640	Inhibition of excitatory nonâ€adrenergic nonâ€cholinergic bronchoconstriction in guineaâ€pig airways <i>in vitro</i> by activation of an atypical 5â€HT receptor. British Journal of Pharmacology, 1994, 111, 1095-1102.	5.4	16
641	LIGAND-INDUCED DIFFERENTIATION OF GLUCOCORTICOID RECEPTOR (GR) TRANS-REPRESSION AND TRANSACTIVATION. Biochemical Society Transactions, 1996, 24, 267S-267S.	3.4	16
642	Molecular Basis for Corticosteroid Action in Asthma. , 2000, 78, 72-80.		16
643	Normal Bronchial Blood Flow in COPD Is Unaffected by Inhaled Corticosteroids and Correlates With Exhaled Nitric Oxide. Chest, 2007, 131, 1075-1081.	0.8	16
644	Oscillating Positive Expiratory Pressure on Respiratory Resistance in Chronic Obstructive Pulmonary Disease With a Small Amount of Secretion. Medicine (United States), 2015, 94, e1845.	1.0	16
645	Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway. Respiratory Research, 2015, 16, 102.	3.6	16
646	Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal, 2018, 51, 1800263.	6.7	16
647	Chronic lung diseases: prospects for regeneration and repair. European Respiratory Review, 2021, 30, 200213.	7.1	16
648	Circulating autoantibodies to recombinant lipocortin-1 in asthma. Respiratory Medicine, 1991, 85, 121-124.	2.9	15

#	Article	IF	CITATIONS
649	Novel therapy for COPD. Expert Opinion on Investigational Drugs, 2000, 9, 3-23.	4.1	15
650	Oxidative/nitrosative stress selectively altered A <sub>2B</sub> adenosine receptors in chronic obstructive pulmonary disease. FASEB Journal, 2010, 24, 1192-1204.	0.5	15
651	The European Respiratory Society plans its future: the 2013-2018 strategic plan. European Respiratory Journal, 2014, 43, 927-932.	6.7	15
652	Effect of formoterol, a longâ€lasting beta 2â€adrenoceptor agonist, against methacholineâ€induced bronchoconstriction British Journal of Clinical Pharmacology, 1990, 29, 321-324.	2.4	14
653	2. What Is the Role of Nerves in Chronic Asthma and Symptoms?. American Journal of Respiratory and Critical Care Medicine, 1996, 153, S5-S8.	5.6	14
654	Osteoprotegerin in Sputum Is a Potential Biomarker in COPD. Chest, 2011, 140, 76-83.	0.8	14
655	Decreased percentage of CD4+Foxp3+TGF-β+ and increased percentage of CD4+IL-17+ cells in bronchoalveolar lavage of asthmatics. Journal of Inflammation, 2014, 11, 22.	3.4	14
656	Asthma mechanisms. Medicine, 2016, 44, 265-270.	0.4	14
657	Bicaudal D1 impairs autophagosome maturation in chronic obstructive pulmonary disease. FASEB BioAdvances, 2019, 1, 688-705.	2.4	14
658	Autoradiographic localization of leukotriene C4 and D4 binding sites in guinea-pig lung. Prostaglandins, 1988, 35, 503-513.	1.2	13
659	Future drug therapy for asthma. Clinical and Experimental Allergy, 1991, 21, 80-85.	2.9	13
660	Oxidative stress induces NFkB DNA binding and inducible NOS mRNA in the human epithelial cell line A549. Biochemical Society Transactions, 1994, 22, 186S-186S.	3.4	13
661	Exhaled nitric oxide. Current Opinion in Anaesthesiology, 1996, 9, 542-548.	2.0	13
662	Asthma guidelines: recommendations versus reality. Respiratory Medicine, 2004, 98, S1-S7.	2.9	13
663	A Single Inhaler for Asthma?. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 95-96.	5.6	13
664	Calcium, Calcium Channel Blockade and Airways Function. Acta Pharmacologica Et Toxicologica, 1986, 58, 91-111.	0.0	13
665	Repeated lipopolysaccharide exposure causes corticosteroid insensitive airway inflammation via activation of phosphoinositide-3-kinase δ pathway. Biochemistry and Biophysics Reports, 2016, 7, 367-373.	1.3	13
666	Effects of an Airway Clearance Device on Inflammation, Bacteriology, and Mucus Transport in Bronchiectasis. Respiratory Care, 2017, 62, 1067-1074.	1.6	13

#	Article	IF	CITATIONS
667	Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model. Journal of Immunology, 2020, 205, 2489-2498.	0.8	13
668	Targeting cellular senescence as a new approach to chronic obstructive pulmonary disease therapy. Current Opinion in Pharmacology, 2021, 56, 68-73.	3.5	13
669	Chemokine receptor CXCR2 antagonism to prevent airways inflammation. Drugs of the Future, 2011, 36, 465.	0.1	13
670	Effect of nitric oxide synthesis inhibition with nebulized L-NAME on ventilation-perfusion distributions in bronchial asthma. European Respiratory Journal, 1998, 12, 865-871.	6.7	12
671	New treatments for asthma. European Journal of Internal Medicine, 2000, 11, 9-20.	2.2	12
672	Pathophysiology of Asthma. , 2002, , 343-359.		12
673	Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients. Respiratory Medicine, 2011, 105, 1784-1789.	2.9	12
674	Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping. Biochemical and Biophysical Research Communications, 2012, 417, 996-1001.	2.1	12
675	Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation. European Respiratory Journal, 2019, 54, 1802390.	6.7	12
676	Evaluation of Individuals at Risk for COPD: Beyond the Scope of GOLD. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 653-667.	0.7	12
677	The Pressing Need to Redefine "COPD". Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 380-383.	0.7	12
678	Differential effects of phosphoramidon on neurokinin A―and substance Pâ€induced airflow obstruction and airway microvascular leakage in guineaâ€pig. British Journal of Pharmacology, 1991, 104, 945-949.	5.4	11
679	Role of Endothelium in the Control of Pulmonary Vascular Tone. Endothelium: Journal of Endothelial Cell Research, 1994, 2, 11-33.	1.7	11
680	Future treatments. BMJ: British Medical Journal, 2006, 333, 246-248.	2.3	11
681	Hepatocyte Growth Factor Deficiency in COPD. Chest, 2014, 146, 1135-1136.	0.8	11
682	Impaired Dual-Specificity Protein Phosphatase DUSP4 Reduces Corticosteroid Sensitivity. Molecular Pharmacology, 2017, 91, 475-481.	2.3	11
683	GOLD 2017. Chest, 2017, 151, 245-246.	0.8	11
684	COUNTERPOINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? No. Chest, 2017, 151, 17-20.	0.8	11

#	Article	IF	CITATIONS
685	Overcoming steroid insensitivity in smoking asthmatics. Current Opinion in Investigational Drugs, 2008, 9, 470-7.	2.3	11
686	Sputum Induction as a Method of Analyzing Pulmonary Cells: Reproducibility and Acceptability. Journal of Asthma, 1999, 36, 335-341.	1.7	10
687	The management of newly identified asthma in primary care in England. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2002, 11, 120-122.	2.3	10
688	We are retracting the article entitled "Emerging Targets for COPD Therapy" by Peter J. Barnes published in Current Drug Targets Inflammation & Allergy. 2005 Dec;4(6):675-683. Inflammation and Allergy: Drug Targets, 2005, 4, 675-683.	3.1	10
689	Protein tyrosine phosphatase PTP-RR regulates corticosteroid sensitivity. Respiratory Research, 2016, 17, 30.	3.6	10
690	Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells. Journal of Critical Care, 2018, 44, 161-167.	2.2	10
691	Can We Define Asthma-COPD Overlap (ACO) by Biomarkers?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 146-147.	3.8	10
692	Effect of inhaled platelet-activating factor on circulating neutrophils and platelets in vivo and ex vivo in man. Prostaglandins, 1988, 36, 343-354.	1.2	9
693	Effect of frusemide on the induction and potentiation of cough induced by prostaglandin F2 alpha British Journal of Clinical Pharmacology, 1992, 33, 514-516.	2.4	9
694	Defective Antioxidant Gene Regulation in COPD: A Case for Broccoli. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 552-554.	5.6	9
695	What the Journal Would Like to Publish on Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1-2.	5.6	9
696	The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. Journal of Allergy and Clinical Immunology, 2015, 136, 501-502.e6.	2.9	9
697	Autoradiographic mapping of beta-adrenoceptors in human skin. Archives of Dermatological Research, 1996, 288, 549-553.	1.9	9
698	Telomere Shortening in Alveolar Macrophages of Smokers and COPD Patients~!2010-02-18~!2010-03-05~!2010-04-15~!. The Open Pathology Journal, 2010, 4, 23-29.	1.0	9
699	Effect of nedocromil sodium on down-regulation of pulmonary β-adrenoceptors. Clinical Science, 1989, 76, 599-602.	4.3	8
700	Isoprostanes and asthma. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 287-292.	0.5	8
701	Drugs for airway disease. Medicine, 2008, 36, 181-190.	0.4	8
702	Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach. Journal of Clinical Medicine, 2020, 9, 2623.	2.4	8

#	Article	IF	CITATIONS
703	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Safety, 2021, 44, 467-478.	3.2	8
704	Modulation of Neurotransmitter Release from Airways Nerves. , 1994, , 209-259.		8
705	Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD. Thorax, 2022, 77, 616-620.	5.6	8
706	IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD. JCI Insight, 2022, 7, .	5.0	8
707	Increased Eosinophil Responsiveness to Platelet-Activating Factor in Asthma. Clinical Science, 1988, 74, 5P-5P.	0.0	7
708	Extracellular signal-regulated kinase 1/2 control Ca2+ -independent force development in histamine-stimulated bovine tracheal smooth muscle. British Journal of Pharmacology, 2000, 131, 981-989.	5.4	7
709	Effect of cigarette smoking on haem-oxygenase expression in alveolar macrophages. Respiratory Medicine, 2004, 98, 530-535.	2.9	7
710	A DPOC como uma doença de envelhecimento acelerado**Chest Translating Basic Research Into Clinical Practice 2009; 135:173-180. Revista Portuguesa De Pneumologia, 2009, 15, 743-746.	0.7	7
711	Neuropeptides as Modulators of Airway Function. , 1990, 31, 175-196.		7
712	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 2019, 23, 1-146.	2.8	7
713	CIRCULATING CATECHOLAMINES IN ASTHMA. Clinical Physiology, 1981, 1, 89-93.	0.7	6
714	Neurogenic inflammation in the airways. NeuroImmune Biology, 2003, , 437-449.	0.2	6
715	Inflammation in COPD. Clinical Respiratory Journal, 2011, 5, 1-2.	1.6	6
716	Chronic obstructive pulmonary disease: important advances. Lancet Respiratory Medicine,the, 2013, 1, e7-e8.	10.7	6
717	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	2.4	6
718	Zafirlukast (Accolate). Drugs of Today, 1998, 34, 375.	1.1	6
719	New treatments for chronic obstructive pulmonary disease. Annali Dell'Istituto Superiore Di Sanita, 2003, 39, 573-82.	0.4	6
720	Autonomic Control of Airway Function in Asthma. Chest, 1987, 91, 45S-48S.	0.8	5

#	Article	IF	CITATIONS
721	Effects of Nedocromil Sodium on Airway Microvascular Leakage and Neural Reflexes. Drugs, 1989, 37, 94-100.	10.9	5
722	Biochemical and pharmacological interactions between the papaverine derivative, AH 21–132, and methacholine in bovine tracheal smooth muscle. European Journal of Pharmacology, 1990, 183, 2157-2158.	3.5	5
723	Localization of beta pre-protachykinin mRNA in nodose ganglion. Neuropeptides, 1991, 20, 145-150.	2.2	5
724	Endotoxin and steroid effects on nitric oxide synthase mRNA expression in rat lung and other tissues. Biochemical Society Transactions, 1994, 22, 188S-188S.	3.4	5
725	The mode of action of corticosteroids in asthma. Research in Immunology, 1998, 149, 225-226.	0.9	5
726	The Need for New Therapy. , 2001, 31, 2-5.		5
727	Cytokine-directed therapies in asthma. Allergology International, 2003, 52, 53-63.	3.3	5
728	New drugs and targets for asthma and COPD. Progress in Respiratory Research, 2010, , 3-23.	0.1	5
729	Drugs for airway disease. Medicine, 2012, 40, 228-237.	0.4	5
730	Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2014, 35, xiii.	2.1	5
731	Reduced denitration activity in peripheral lung of chronic obstructive pulmonary disease. Tanaffos, 2012, 11, 23-9.	0.5	5
732	Current and future therapies for airway mucus hypersecretion. Novartis Foundation Symposium, 2002, 248, 237-49; discussion 249-53, 277-82.	1.1	5
733	Is inhaler technique adequately assessed and reported in clinical trials of asthma and COPD therapy? A systematic review and suggested best practice checklist Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	5
734	Platelet Activating Factor Increases Vascular Permeability in Guinea Pig Airways. Clinical Science, 1986, 71, 1P-1P.	0.0	4
735	Activation of guinea pig eosinophil respiratory burst by leukotriene B <sub>4</sub> : role of protein kinase C. Fundamental and Clinical Pharmacology, 1992, 6, 353-358.	1.9	4
736	The trials and tribulations of anti–IL-5 …. Journal of Allergy and Clinical Immunology, 2002, 109, 575.	2.9	4
737	Nuclear factor-kappaB does not mediate the inhibitory effects of dexamethasone on granulocyte-macrophage colony-stimulating factor expression. Immunology, 2004, 111, 430-434.	4.4	4
738	Generating Monodisperse Pharmacological Aerosols Using the Spinning-top Aerosol Generator. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 245-253.	1.2	4

#	Article	IF	CITATIONS
739	A DPOC como uma doença de envelhecimento acelerado. Revista Portuguesa De Pneumologia, 2009, 15, 743-746.	0.7	4
740	David Jack (1924–2011) who revolutionised the treatment of asthma. Thorax, 2012, 67, 266-267.	5.6	4
741	Nitrosative stress in patients with asthmaâ^'chronic obstructive pulmonary disease overlap. Journal of Allergy and Clinical Immunology, 2019, 144, 928-930.	2.9	4
742	No Evidence That Electric Charge Increases Inhaled Ultrafine Particle Deposition in Human Lungs. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1301-1303.	5.6	4
743	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials, 2021, 22, 213.	1.6	4
744	New Concepts in the Pathogenesis of Bronchial Hyperresponsiveness. , 1987, 21, 225-237.		4
745	Transcription Factors. , 1998, , 459-474.		4
746	Glucocorticosteroids. , 1998, , 725-766.		4
747	Exhaled Breath Condensate. , 2004, , 1-9.		4
748	Histamine, Substance P and Neurogenic Flare in Human Skin. Clinical Science, 1985, 68, 23P-24P.	0.0	3
749	Comparison of the Cardiovascular and Respiratory Effects of Substance P and Neurokinin A in Man. Clinical Science, 1987, 72, 41P-41P.	0.0	3
750	The role of neurotransmitters in bronchial asthma. Lung, 1990, 168, 57-65.	3.3	3
751	The lowâ€chloride cough response is not inhibited by a single, high dose of aspirin British Journal of Clinical Pharmacology, 1992, 34, 370-372.	2.4	3
752	CYTOKINE mRNA PROFILES OF NORMAL AND ASTHMATIC PERIPHERAL BLOOD CELLS AND ENDOBRONCHIAL BIOPSIES. Biochemical Society Transactions, 1996, 24, 315S-315S.	3.4	3
753	Asthma Therapy with Aerosols: Clinical Relevance for the Next Decade. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 1996, 9, 131-141.	1.2	3
754	9. Why Does Asthma Become Persistent?. American Journal of Respiratory and Critical Care Medicine, 1996, 153, S23-S25.	5.6	3
755	Neural mechanisms in asthma: New developments. Pediatric Pulmonology, 1997, 23, 82-83.	2.0	3
756	Rebuttal by Dr. Barnes. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 974-974.	5.6	3

#	Article	IF	CITATIONS
757	Chronic obstructive pulmonary disease in non-smokers – Authors' reply. Lancet, The, 2009, 374, 1965-1966.	13.7	3
758	Biology and Assessment of Airway Inflammation. , 2012, , 75-88.		3
759	Painful subcutaneous nodules in a patch of livedo reticularis. International Journal of Dermatology, 2017, 56, e44-e46.	1.0	3
760	Case Report: Ketogenic Diet Is Associated With Improvements in Chronic Obstructive Pulmonary Disease. Frontiers in Medicine, 2021, 8, 699427.	2.6	3
761	Drugs for the treatment of asthma and COPD. , 2005, , 281-344.		3
762	Transcription Factors in Asthma. , 1998, , 25-45.		3
763	Allergic Inflammatory Mediators and Bronchial Hyperresponsiveness. Immunology and Allergy Clinics of North America, 1990, 10, 241-249.	1.9	3
764	Platelet Activating Factor (PAF) Stimulates Phosphoinositide (PI) Metabolism in Guinea Pig Eosinophils. Clinical Science, 1989, 76, 45P-45P.	0.0	2
765	Dilator Action of Ligustrazine on Human and Rat Pulmonary Arteries. Clinical Science, 1989, 77, 27P-27P.	0.0	2
766	Preventative therapy in adults with asthma. Respiratory Medicine, 1991, 85, 355-357.	2.9	2
767	T CELL RECEPTOR REPERTOIRE IN PERIPHERAL BLOOD AND BRONCHIAL BIOPSIES FROM NORMAL AND ASTHMATIC SUBJECTS. Biochemical Society Transactions, 1996, 24, 316S-316S.	3.4	2
768	Reduced Acetylation of Histone 4 in Corticosteroid-Resistant and Corticosteroid-Dependent Asthma. Clinical Science, 2001, 100, 12P-12P.	0.0	2
769	IntroducingExpert Review of Respiratory Medicine. Expert Review of Respiratory Medicine, 2007, 1, 1-2.	2.5	2
770	Pathophysiology of COPD. , 2009, , 425-442.		2
771	Autonomic Control of the Lower Airways. , 2012, , 201-204.		2
772	NANC Nerves and Neuropeptides. , 1998, , 423-457.		2
773	Neuropeptides and Asthma. Allergy and Clinical Immunology International, 2000, 12, 0054-0059.	0.3	2

#	Article	IF	CITATIONS
775	Oxidative Stress in Chronic Obstructive Pulmonary Disease. , 2014, , 314-348.		2
776	Molecular Mechanisms of Anti-Asthma Therapy. , 1995, , 403-409.		2
777	Identification of Novel Therapeutic Targets in COPD. Tanaffos, 2011, 10, 9-14.	0.5	2
778	Immunological Features of Chronic Obstructive Pulmonary Disease (COPD) Induced by Indoor Pollution and Cigarette Smoke. Tanaffos, 2012, 11, 6-17.	0.5	2
779	Update on asthma. Israel Medical Association Journal, 2003, 5, 68-72.	0.1	2
780	Role of Endogenous Opiates in Control of Breathing. Clinical Science, 1981, 61, 4P-5P.	4.3	1
781	Plasma Catecholamine Concentrations in Acute Severe Asthma and Antigen-Induced Bronchoconstriction. Clinical Science, 1984, 67, 34P-35P.	0.0	1
782	Nifedipine Prolongs Isoprenaline-Induced Bronchodilatation in Normal Subjects. Clinical Science, 1984, 67, 62P-62P.	0.0	1
783	The Effect of Posture on Slow Release Theophylline Pharmacokinetics. Clinical Science, 1985, 68, 4P-5P.	0.0	1
784	Inhaled Nifedipine Reverses Histamine-Induced Bronchoconstriction in Man. Clinical Science, 1985, 68, 5P-5P.	0.0	1
785	The Effect of Vasoactive Intestinal Peptide on Human Airway Smooth Muscle in-vitro. Clinical Science, 1985, 68, 58P-58P.	0.0	1
786	The Influence of Epithelium on Airway Smooth Muscle Contraction. Clinical Science, 1985, 68, 59P-59P.	0.0	1
787	Influence of Autonomic Blockade on Cardiovascular effects of Infused Adenosine in Man. Clinical Science, 1986, 71, 45P-45P.	0.0	1
788	Effects of Infused Adenosine on the Cardiovascular Responses to Orthostasis in Man. Clinical Science, 1987, 72, 9P-9P.	0.0	1
789	Effect of A Platelet Activating Factor (PAF) Antagonist (Web 2086) on Paf Induced Airway Microvascular Leakage and Platelet Aggregation. Clinical Science, 1987, 72, 68P-68P.	0.0	1
790	Bradykinin-Induced Microvascular Leakage in Guinea Pig Airways: Involvement of Platelet Activating Factor and Prostanoids. Clinical Science, 1988, 74, 29P-29P.	0.0	1
791	Evidence for Platelet-Activatinc Factor as a Mediator of Hypoxic Pulmonary Vasoconstriction. Clinical Science, 1988, 75, 21P-21P.	0.0	1
792	Functional Characteristics of Beta-Adrenergic Receptors of the Intact Eosinophil. Clinical Science, 1989, 76, 14P-14P.	0.0	1

#	Article	IF	CITATIONS
793	ASTHMA THERAPY ??? PRESENT ANXIETIES AND FUTURE RESEARCH. Adverse Drug Reaction Bulletin, 1992, 154, 579-582.	0.5	1
794	Barnes and Adcock reply. Trends in Pharmacological Sciences, 1994, 15, 139.	8.7	1
795	From pathophysiological mechanisms to pharmacological treatment of childhood asthma. Pediatric Pulmonology, 1995, 19, 40-41.	2.0	1
796	Muscarinic receptor subtypes in airways. Research in Immunology, 1998, 149, 201-202.	0.9	1
797	Clinical Studies on New Drugs. , 2001, 31, 48-51.		1
798	Molecular mechanisms of atopy. Mediators of Inflammation, 2001, 10, 285-288.	3.0	1
799	Are mast cells still important in asthma?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2002, 42, 20-27.	0.1	1
800	Glucocorticosteroids for Asthma. NeuroImmune Biology, 2007, , 359-381.	0.2	1
801	Oxidative Stress Regulates IL-4 Gene Expression In Mast Cells Through Reduction Of Histone Deacetylase (HDAC). Journal of Allergy and Clinical Immunology, 2007, 119, S138.	2.9	1
802	Future therapies for chronic obstructive pulmonary disease. Journal of Organ Dysfunction, 2008, 4, 66-70.	0.3	1
803	A Blood Test for Lung Fibrosis. PLoS Medicine, 2008, 5, e98.	8.4	1
804	Novel mechanisms and new therapies for chronic obstructive pulmonary disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 795-804.	0.2	1
805	Chronic obstructive pulmonary disease: reasons for optimism. Therapy: Open Access in Clinical Medicine, 2009, 6, 769-770.	0.2	1
806	Genomics in the Evaluation and Management of Chronic Obstructive Pulmonary Disease. , 2010, , 603-615.		1
807	C4 Drugs for the treatment of airway disease. , 2011, , 321-357.		1
808	P184â€Macrophage phagocytosis in COPD patients at exacerbation compared to stable state. Thorax, 2013, 68, A159.1-A159.	5.6	1
809	T5â€Circulating endothelial progenitor cells in smokers and patients with COPD are dysfunctional due to increased DNA damage and senescence. Thorax, 2013, 68, A2.3-A3.	5.6	1
810	What Does the Future Hold for the Therapy of COPD?. Milestones in Drug Therapy, 2014, , 129-146.	0.1	1

#	Article	IF	CITATIONS
811	Updates in Chronic Obstructive Pulmonary Disease for the Year 2014. Turkish Thoracic Journal, 2015, 16, 86-96.	0.1	1
812	Inflammatory Mechanisms in Chronic Obstructive Pulmonary Disease. , 2017, , 1173-1198.		1
813	Oxidative Stress in COPD. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 115-129.	0.4	1
814	Pathophysiology of Allergic Inflammation. , 2009, , 455-472.		1
815	Automated multiwell plate STORM: towards open source super-resolved high content analysis. , 2019, , $\cdot$		1
816	Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. , 2018, , .		1
817	Exacerbation risk after night-time waking due to asthma in SYGMA 1. , 2019, , .		1
818	Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. , 2019, , .		1
819	CHRONIC OBSTRUCTIVE PULMONARY DISEASE   Overview. , 2006, , 429-439.		1
820	The Future of COPD. , 2011, , 75-90.		1
821	Pathophysiology of Allergic Inflammation. , 2014, , 327-342.		1
822	Transcription Factors and Inflammatory Lung Disease. , 1999, , 41-70.		1
823	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. , 2018, , .		1
824	COPD and Asthma: Effects Beyond the Respiratory System. Tanaffos, 2012, 11, 9.	0.5	1
825	Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19. European Respiratory Journal, 2022, , 2200754.	6.7	1
826	Hypoxia and Catecholamine Secretion in Normal Man. Clinical Science, 1984, 67, 58P-59P.	0.0	0
827	Regional Ventilation Perfusion Ratio and Specific Ventilation in Asthmatics Using Positron Emission Tomography (PET). Clinical Science, 1984, 67, 59P-60P.	0.0	0
828	Distribution of Beta-Adrenoceptor Subtypes in Human Lung. Clinical Science, 1985, 68, 35P-35P.	0.0	0

#	Article	IF	CITATIONS
829	Substance P Enhances the Transient Ventilatory Hypoxic Response in Man. Clinical Science, 1985, 69, 59P-59P.	0.0	0
830	A Comparison of the Cutaneous Actions of Substance P and Calcitonin Gene Related Peptide in Man. Clinical Science, 1986, 70, 54P-54P.	0.0	0
831	Why a new journal?. Pulmonary Pharmacology, 1988, 1, 1.	0.6	0
832	Neuropeptides and asthma. European Journal of Pharmacology, 1990, 183, 94.	3.5	0
833	Nitric oxide in lung disorders. Biomedicine and Pharmacotherapy, 1994, 48, 409.	5.6	0
834	Dexamethasone action on <i>c-fos</i> and <i>c-jun</i> mRNA and protein in human lung. Biochemical Society Transactions, 1994, 22, 187S-187S.	3.4	0
835	Use of a Fixed Combination β2-Agonist and Steroid Dry Powder Inhaler in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 1053-1057.	5.6	0
836	Pathophysiology of Asthma. , 1998, , 487-506.		0
837	Mediator Antagonists. , 1998, , 767-782.		0
838	Recommendations based on guidelines on the management of mild to moderately severe chronic obstructive pulmonary disease: some practical applications in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 1998, 6, 35-39.	2.3	0
839	Salmeterol/Fluticasone Propionate Combination. Drugs, 1999, 57, 941-943.	10.9	0
840	Eosinophils and airway hyper-responsiveness. Lancet, The, 2001, 357, 1446.	13.7	0
841	Montelukast for persistent asthma. Lancet, The, 2001, 358, 1455-1456.	13.7	0
842	Current Therapy for Asthma. , 2001, 31, 6-10.		0
843	Drugs for airway disease. Medicine, 2003, 31, 44-51.	0.4	0
844	How To Design a Negative Study. Chest, 2003, 123, 656.	0.8	0
845	Interleukin-6, Obstructive Sleep Apnea, and Obesity. Chest, 2003, 124, 1622-1623.	0.8	0

#	Article	IF	CITATIONS
847	Autonomic Control of Airways. , 2004, , 130-133.		Ο
848	Histamine levels following adenosine monophosphate challenge. Respiratory Medicine, 2005, 99, 516.	2.9	0
849	Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler. Drugs, 2006, 66, 1484-1485.	10.9	0
850	CORTICOSTEROIDS   Therapy. , 2006, , 576-581.		0
851	BRONCHODILATORS   Theophylline. , 2006, , 292-296.		Ο
852	Beyond the Dutch Hypothesis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1057-1057.	5.6	0
853	New aspects of chronic obstructive pulmonary disease. Journal of Organ Dysfunction, 2007, 3, 240-249.	0.3	0
854	Avancées thérapeutiques pouvant modifier l'évolution clinique de la BPCO. Revue Des Maladies Respiratoires, 2008, 25, 16-20.	1.7	0
855	Genomic Aspects of Chronic Obstructive Pulmonary Disease. , 2009, , 1098-1109.		О
856	Neural and Humoral Control of the Airways. , 2009, , 381-397.		0
857	Pathophysiology of Asthma. , 2009, , 399-423.		О
858	Anticholinergic Bronchodilators. , 2009, , 615-626.		0
859	Mediator Antagonists. , 2009, , 655-662.		О
860	Future Therapies. , 2009, , 737-749.		0
861	Rescue Treatment in Asthma: Response. Chest, 2010, 137, 240-241.	0.8	0
862	Involvement Of P38MAPK Gamma On Corticosteroid Refractory Airway Inflammation Induced By Tobacco Smoke In Mice. , 2010, , .		0
863	Addressing Unmet Medical Needs in COPD Management. , 2012, , .		0
864	P253â€Association of Defective Monocyte-Derived Macrophage Phagocytosis with Clinical Phenotypes in Stable COPD. Thorax, 2012, 67, A175.2-A176.	5.6	0

0

#	Article	IF	CITATIONS
865	Therapy of Airway Disease. , 2012, , 387-393.		Ο
866	Anti-Inflammatory Therapeutics in COPD: Past, Present, and Future. , 2013, , 191-213.		0
867	Exhaled Nitric Oxide in Clinical Practice: Recent Advances and New Challenges. , 2013, , 231-241.		0
868	S66â€Targeting anti-ageing molecule AMPK restores corticosteroid sensitivity in COPD. Thorax, 2013, 68, A36.1-A36.	5.6	0
869	S112â€HDAC activity in macrophages in experimental rhinovirus infection in COPD. Thorax, 2013, 68, A58.2-A59.	5.6	0
870	Giants in Chest Medicine. Chest, 2014, 146, 545-546.	0.8	0
871	Giants in Chest Medicine. Chest, 2016, 149, 619-620.	0.8	0
872	Professor Neil B.ÂPride (1931–2016). European Respiratory Journal, 2017, 49, 1602343.	6.7	0
873	Rebuttal From Dr Barnes. Chest, 2017, 151, 21-22.	0.8	0
874	P53â€Phosphoinositide-3 kinase and mek inhibition prevents uptake of bacteria by airway epithelial cells. , 2017, , .		0
875	5â€Therapy for asthma and COPD. , 2018, , .		0
876	Dynein Has Defective Activity in COPD Macrophage Phagocytosis. , 2019, , .		0
877	Accelerated Lung Aging and Cellular Senescence in COPD. , 2022, , 583-593.		0
878	Other Drugs for Asthma and COPD. , 2022, , 729-740.		0
879	Inflammatory and Immune Mechanisms in COPD. , 2022, , 549-558.		0
880	Asthmatic patients. , 2021, , 136-153.		0
881	Nitric Oxide in Exhaled Air: Relevance in Inflammatory Lung Disease. , 2000, , 167-183.		0

The Pathogenesis and Treatment of Asthma as an Inflammatory Disease. , 2000, , 221-236.

#	Article	IF	CITATIONS
883	Inflammatory Mediators and Neural Mechanisms in Severe Asthma. Lung Biology in Health and Disease, 2001, , 67-87.	0.1	0
884	Future Therapies. , 2002, , 641-656.		0
885	Future Therapies for Asthma. Lung Biology in Health and Disease, 2002, , 353-382.	0.1	0
886	Autonomic Control of the Airways. , 2002, , 432-454.		0
887	Glucocorticoids and Asthma. , 2003, , 127-134.		0
888	New drugs for COPD based on advances in pathophysiology. , 2004, , 189-226.		0
889	Oxidative Stress in COPD. , 2004, , 61-74.		0
890	Biology and Assessment of Airway Inflammation. , 2006, , 65-74.		0
891	$\hat{I}^2$ 2-Agonists, Anticholinergics, and Other Nonsteroid Drugs. , 2008, , 471-482.		0
892	Signal Transduction Pathways Involved in Glucocorticoid Actions. , 2010, , 289-309.		0
893	Pharmacologic Principles. , 2010, , 159-199.		0
894	Targeting Histone Deacetylases in Chronic Obstructive Pulmonary Disease. , 2011, , 205-215.		0
895	Epidemiology, Risk Factors and Pathophysiology. , 2011, , 7-28.		0
896	The Future of COPD. , 2013, , 77-92.		0
897	COPD: inflammatory mechanisms and systemic consequences. , 2013, , 13-27.		0
898	Future Therapies for Asthma. , 1998, , 795-819.		0
899	New Targets for Future Asthma Therapy. , 1999, , 361-389.		0
900	Anti-inflammatory effects of resveratrol analogues in cellular models of airway inflammation. , 2015,		0

#	Article	IF	CITATIONS
901	LSC Abstract – Rhinovirus infection induces NRF2 in monocytes but not in epithelial cells, via distinct intracellular pathways. , 2015, , .		0
902	Recent Advances in Asthma Management. European Respiratory & Pulmonary Diseases, 2018, 4, 15.	0.2	0
903	Pharmacology of asthma and COPD. , 2019, , 344-352.		0
904	Differential phosphorylation patterns of macrophage cytoskeletal proteins in COPD following phagocytosis. , 2019, , .		0
905	Towards easier, faster, super-resolved microscopy. , 2020, , .		0
906	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function― Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4179-4180.	3.8	0
907	Extracellular vesicles produced by airway epithelial cells in response to oxidative stress contain microRNAs associated with cellular senescence. , 2021, , .		0
908	IL-36? $\hat{a} \in \hat{a}$ a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease. , 2021, , .		0
909	Altered iron metabolism and elevated cellular senescence in COPD small airway epithelial cells. , 2020, , .		0
910	Analysis of defective phagocytosis in COPD using super-resolution microscopy and automated bacterial quantification. , 2020, , .		0
911	Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2. , 2020, ,		0
912	LSC - 2020 - Extracellular vesicles produced by bronchial epithelial cells in response to oxidative stress contain micro-RNAs associated with senescence. , 2020, , .		0
913	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial. International Journal of COPD, 2022, Volume 17, 273-282.	2.3	0
914	Chemokine receptor CCR1: new target for asthma therapy. Trends in Pharmacological Sciences, 2022, , .	8.7	0